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1 INTRODUCTION 
1.1 Cancer gene therapy 
Within the area of gene therapy, the treatment of malignant diseases is, with 64.3% of all 
gene therapy trials performed worldwide, the main area of application (Figure 1, The 
Journal of Gene Medicine, 2013). Cancer gene therapy employs DNA as a pharmaceutical 
agent to treat cancer. The method can either be used to introduce a functional gene to 
replace a mutated gene (gene replacement strategies) as performed with the tumor 
suppressor gene p53,1 by delivering DNA that encodes for an enzyme e.g. the thymidine 
kinase gene of herpes simplex virus (HSV-TK) able to convert non-toxic prodrugs into 
active chemotherapeutic agents selectively within the tumor 2 (suicide gene therapy) or by 
priming the patient’s immune system e.g. by transducing tumor cells so that they secrete 
granulocyte macrophage colony stimulating factor (GM-CSF) or interleukin-12 (gene 
based immunotherapy).3 The two major methods by which the DNA is delivered include 
the use of naked DNA or DNA complexes as non-viral vectors and the utilization of 
recombinant viruses as viral gene transfer vehicles. 
 
 
Figure 1. Percentage and absolute number of indications addressed by gene therapy clinical trials 
Adapted from www.wiley.co.uk/genmed/clinical (The Journal of Gene Medicine, 2013) 
 
1.2 Adenovirus vectors in cancer gene therapy 
To date adenovirus vectors are the most commonly studied and most widely used vectors 
in cancer gene therapy (Figure 2, The Journal of Gene Medicine, 
www.wiley.co.uk/genmed/clinical). Since its detection in adenoid tissue by Rowe in 1953,4 
there are currently 57 described serotypes 5 in humans belonging to the genus 
Mastadenovirus. Based on oncogenicity in rodents, hemagglutination properties of human, 
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monkey and rat erythrocytes, DNA sequence similarity and serologic profiles, the human 
adenoviruses can be further divided into species A -G.6 Adenoviruses can be easily 
genetically manipulated to generate either replication incompetent or conditionally 
replicating viruses. Replication incompetent adenoviruses can be classified into three 
categories: vectors of the first generation contain deletions in the E1 regions required for 
viral replication and often have an additional E3 region deletion. Second generation 
vectors possess additional deletions in the E2 and E4 regions. Third generation vectors 
finally are devoid of all viral genes with the exception of inverted terminal repeats and 
DNA packing sequences. These gutless or helper-dependent vectors are characterized by a 
reduced immunogenicity and an extended transgene expression. In the case of replication 
incompetent adenoviruses, the anti-tumor activity is caused by the transgene delivered. In 
contrast conditionally replicating adenoviruses, also referred to as oncolytic adenoviruses, 
are able to selectively replicate in cancer cells, leading to the death of cancer cells through 
cell lysis, mediated during viral spread.7 They hold great promise as potent, self amplifying 
cancer therapeutics, while showing no cross-resistance with chemo- and radiation 
therapies. 8 These oncolytic adenoviruses can be further armed with therapeutic transgenes 
like prodrug convertase transgenes (HSV-TK), pro apoptotic transgenes (p53, TRAIL) or 
immunoactivating transgenes (INF, GM-CSF).8 
The most employed adenovirus vectors in clinical trials are serotype 5 (Ad) based vectors, 
belonging to species C, with a growing number of trials advancing to Phase III. The main 
focus lies on the delivery of the tumor suppressor gene p53 as gene replacement strategy, 
often combined with conventional chemotherapy.9 One example is a US Phase III 
multicenter, open-label, randomized study, where the effectiveness and safety of bi-weekly 
intratumoral administration of Ad p53 (INGN 201) in combination with chemotherapy is 
compared with chemotherapy alone in 288 patients with recurrent squamous cell 
carcinoma of the head and neck. It is known that tumor cells expressing wild-type p53 are 
more sensitive to chemotherapeutic agents and radiation, than cells lacking functional 
p53.9 Chemotherapy, in return, enhances expression of transduced genes from adenoviral 
vectors.9 Also radiation enables a synergistic effect as it improves immediate adenoviral 
transduction efficiency and the duration of transgene expression.10 Adenoviral gene 
therapy can therefore be used to support standard anti-tumor therapies like chemotherapy 
or radiation.  
In China there are already two Ad-based products, which have been approved by the 
Chinese State Food and Drug Administration for the use in patients suffering from head 
and neck carcinoma: Gendicine™ 11 a replication-incompetent recombinant human Ad-p53 
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and Oncorine™ (H101) 12 a conditionally replicative adenovirus, carrying a deletion of the 
E1B-55 kDa/E3B genes (normally allowing the Ad to bind and inactivate the host p53 
gene in order to promote its own replication),13 developed to selectively replicate in tumor 
cells with dysfunctional p53 genes. The utilization of adenoviral vectors is especially 
beneficial, when temporary gene expression is desired, as in the case of cancer treatment. 
 
 
Figure 2. Percentage and absolute numbers of vectors used in gene therapy clinical trials 
Adapted from www.wiley.co.uk/genmed/clinical (The Journal of Gene Medicine, 2013) 
 
1.3 Adenovirus structure 
The adenovirus is a non-enveloped double stranded DNA virus, with a genome size of 
about 36 kb,14 showing an icosahedral symmetry and a size between 70 and 90 nm.15 The 
viral particle is built out off 13 structural proteins (Figure 3).16 Four proteins surround the 
genome forming a nucleoprotein core complex, composed of a core-penton bridging 
protein (V), histone-like protein (VII), Mu protein and terminal protein (TP) covalently 
bound to the 5’ end of the genome.17 Two more proteins are associated with the core, IVa2 
18
 and the protease.6 The capsid consists of seven proteins, namely the trimeric hexon (II), 
with its stabilizing minor capsid proteins (VI, VIII and IX), the pentameric penton base, 
the penton associated protein (IIIa), responsible to bridge hexon and penton and the 
trimeric fiber protein (IV), which protrudes at the 12 vertices of the icosahedral capsid.19,20 
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Figure 3. Adenovirus structure 
Scheme of capsid and core proteins of an adenovirus (W.C. Russell, J. of General Virology, 2009)6 
 
1.4 Entry pathway of adenovirus type 5 (Ad) in vitro 
The adenovirus type 5 (Ad) infects its target cells through a two step entry pathway (Figure 
4): the fiber knob protein of the Ad capsid binds to the coxsackie- and adenovirus receptor 
(CAR) for cell attachment,21 as does the KKTK (Lys-Lys-Thr-Lys) motive of the fiber 
shaft to heparan sulfate proteoglycans (HSPG).22 This is followed by an interaction of the 
RGD (Arg-Gly-Asp) motif in the penton base protein with the cell surface αvβ3 and αvβ5 
integrins, leading to internalization.23 Additional integrins including αvβ1, α3β1, α5β1 and 
αMβ2 have also been identified as receptors facilitating internalization, in vitro.24-27 The 
internalization process is caused via clathrin-mediated endocytosis.28 Partial capsid 
disassembly upon acidification of the endosome leads to exposure of protein VI, which 
then modulates endosomal escape by its lytic action.29 Thereafter the nucleocapsid-hexon 
core is transported in a microtubule dependent manner to the nuclear pore complex, 
involving dynein for attachement.30 After binding to the nuclear pore complex receptor 
CAN/Nup214 and recruitment of Hsc70, nuclear histone H1 and H1 import factors 
importin β and importin 7, complete capsid disassembly is facilitated and the viral genomic 
DNA delivered into the nucleus.31 
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Figure 4. In vitro entry pathway of adenovirus type 5 (Ad) (L. Coughlan, Viruses, 2010)16 
1. Ad attachment is mediated by binding of the fiber knob to CAR. 2. Interaction between the RGD 
motif of the penton base and αvβ3/5 integrins triggers internalization by clathrin-mediated 
endocytosis. 3. Partial disassembly of the capsid is induced upon acidification of the endosome. 
Endosomal escape is modulated through the lytic action of protein VI. 4. The nucleocapsid-hexon 
core is translocated to the nuclear pore complex (NPC) along the microtubule network using the 
microtubule-associated motor, dynein. 5. Final dissociation of the capsid at the NPC 32 allows the 
core DNA to extrude into the nucleus leading to subsequent transcription and in case of replication 
competent Ad, to induction of a replication cycle. 
 
1.5 Advantages and disadvantages of Ad versus non-viral vectors 
The adenovirus type 5 (Ad) is the most frequently used vector in gene therapy clinical 
trials as it has a number of features which favor effective gene transfer. Ad has the 
advantage of a high transduction efficiency in many cell types.33 It can infect dividing as 
well as non-dividing and differentiated cells without integrating its DNA into the host 
genome, therefore exhibiting a limited rate of insertional mutagenesis.14 Additionally Ad 
can accommodate large segments of foreign DNA, with a volume of up to 7.5 kb for first-
generation vectors and up to 36 kb in the case of gutless vectors.34 The transgenic protein 
can be expressed at high levels of up to 35% of the total cellular protein. Titers up to 1013 
VP/ml can be produced 35 and virus biology is well characterized. Moreover the vectors are 
stable, when administered into the bloodstream. Still the in vivo application of Ad faces 
significant hurdles (Figure 5):  
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Figure 5. Interactions of Ad with blood components in vivo (L. Coughlan, Viruses, 2010)16 
1. Binding of Ad to CAR-expressing erythrocytes can cause trapping of virus in the circulation. In 
the presence of antibody and complement, Ad can bind human erythrocytes via CR-1. 2. 
Opsonization of Ad with natural IgM and/or complement promotes Kupffer cell (KC) uptake via 
complement receptor-3 (CR-3) or Fc Receptor. 3. Ad interactions with CD4+ T-cells. 4. FX 
binding to the Ad hexon promotes hepatocyte entry through HSPGs (heparan sulphate 
proteoglycans). 5. FIX/C4BP binding to the fiber knob has been proposed to mediate hepatocyte 
entry via HSPGs or LRP (Low density lipoprotein receptor), and has been suggested to direct KC 
uptake 36. 6. Ad binding to platelets has been shown to enhance uptake by KCs.37 Von Willebrand 
factor (vWF) and P-selectin have been associated with the formation of activated platelet-leukocyte 
aggregates which are cleared by scavenging macrophages.38 
 
After intravenous application of Ad the majority of the particles are scavenged by resident 
liver macrophages, called Kupffer cells (KCs) and spleen macrophages. Following 
opsonization of Ad by immunoglobulin M antibodies and complement system, uptake in 
KCs is directed via complement receptor-3 (CR3) or Fc receptor interations.39,40 Also 
scavenging receptor-A (SR-A) has been proposed to be involved in Ad uptake by KCs, 
presumably recognizing the negative charge of the virus capsid.41 Besides being rapidly 
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removed from the blood circulation, scavenging by KCs is accompanied by the release of 
inflammatory cytokines contributing to the acute liver toxicity. After saturation of the 
reticuloendothelial system the Ad is predominantly taken up by hepatocytes.42 A recently 
identified high affinity interaction between coagulation factor X and the hexon protein, 
leads to this hepatocyte infection after intravenous application in vivo.43-45 Additionally 
most humans possess antibodies against Ad, due to Ad contact early in life. This leads to 
neutralization of Ad by preexisting antibodies, causing a strong reduction of target cell 
infection.46-48 Yet another problem to solve is that the transduction efficiency is limited by 
the level of viral receptors on target cells, which are often downregulated on cancer cells, 
correlating with the aggressiveness of the tumor.49 On the other hand, non-target cells may 
express high levels of receptors precluding target selectivity. An important difference 
between mouse and man, which has to be taken into consideration, when establishing a 
mouse model, where the vector is applied intravenously, is the fact that in humans Ad 
binds to erythrocytes leaving only 1% unbound. This on the one hand increases circulation 
times, but on the other hand precludes vector extravasation into target tissue.50 In principal 
adenoviral vectors are well tolerated, proven through several phase I clinical trials, 
showing minimal side effects like shivering, light fever, chills, local pain and diarrhea after 
intratumoral administration of 1x1012 viral particles.9 Despite this, a general skepticism 
still pervades since the death of 18 year old Jesse Gelsinger in 1999, who participated in a 
Phase I clinical trial for ornithine transcarbamylase deficiency. 98 h following 
intravascular administration of 3.8x1013 virus particles he died due to systemic 
inflammatory response syndrome, disseminated intravascular coagulation, accumulation of 
ammonia in the blood due to the underlying metabolic deficiency and ultimately 
multiorgan failure.35 This tragic incident led to several considerations. By minimizing the 
transcribed viral genes through the further development of second and third generation 
vectors, measuring vector concentration in plaque forming units (PFU) and additionally in 
viral particles (VP) and taking into account liver function and underlying diseases before 
systemic administration of Ad, safety could have been improved.51 
As an alternative to viral vectors, synthetic gene delivery systems have evolved, like 
cationic lipids or polymers,52 which are able to condense DNA forming a positively 
charged complex that can enter the cell and escape the endosome via a proton sponge 
effect.53 In contrast to viral vectors, which are restricted mainly to DNA and RNA 
delivery, non-viral vectors are able to deliver proteins, synthetic oligonucleotides and small 
compounds beside DNA and RNA.52 Such vectors have the advantage that no preformed 
antibodies exist, which could prevent a successful infection. In addition non-viral vectors 
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have the ability to carry large therapeutic genes (52 kb) 54 and cheap large scale 
manufacture is possible.55 Furthermore, modification with hydrophilic polymers, like 
polyethyleneglycol (PEG), enables prolonged circulation of drugs and gene vectors in the 
bloodstream, avoiding entrapment by reticuloendothelial cells in the liver, spleen and lung 
therefore allowing accumulation in tumor tissue.56 Synthetic delivery systems can also be 
designed in a modular way, which allows the incorporation of cell targeting and 
internalizing ligands considerably improving their efficiency and specificity.57 Still, there 
are major hurdles for non-viral gene delivery vectors to overcome like poor nuclear import 
and the absence of a transcriptional enhancer, making them far less effective compared to 
their viral counterparts.58  
The limited clinical applicability of adenoviral vectors, caused by several vector–host 
interactions, could be widened by using polycationic coating to cover the sides responsible 
for interaction. A combination of both systems would be therefore beneficial to achieve a 
high transgene expression level even in cells not accessible by Ad itself and at the same 
time enable e.g. protection from inactivation by neutralizing antibodies.  
 
1.6 Transductional targeting 
1.6.1 Genetic modification strategies 
Transductional targeting, which is based on directed binding of Ad to and uptake in target 
cells, away from its natural tropism, is primarly achieved by genetic targeting strategies. 
The genetic incorporation of targeting ligands is tolerated at specific sites of the Ad capsid 
including the C-terminus 59 and the H1 loop 60 of the fiber, the penton base,61 certain 
hypervariable regions of the hexon 62 and the pIX protein.59 Therefore it is important that 
the inserted ligand doesn’t disrupt adequate capsid assembly. Besides a limitation in size of 
the inserted ligand, functionality of the targeting peptide must be retained without the 
necessity for major post-translational modifications.16 Ligands successfully inserted into 
the H1 loop and C-terminus of the fiber include RGD 63 and polylysine motifs binding to 
αvβ3/5 integrins and heparan sulphate proteoglycans respectively. Furthermore genetic 
pseudotyping is used, where e.g. the adenovirus type 5 fiber is substituted by fibers derived 
from species B adenoviruses, leading to CAR-independent target cell infection via 
receptors including CD46 64, CD80 and CD86.65 A drawback of this approach is, that 
genetic pseudotyping has been shown to alter intracellular trafficking of Ads, leading to 
inefficient endosomal escape 66 or a slow-down in nuclear translocation.  
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1.6.2 Chemical modification: non-covalent versus covalent 
Additionally, transductional targeting can be gained chemically either via non-covalent or 
covalent surface modification of the viral capsid. Due to its net negative surface charge, Ad 
capsids can be easily coated with (poly)cationic molecules by non-covalent charge 
interaction. This allows for a fast screening of suitable polycationic coating agents. 
Fasbender et al. were the first to demonstrate the prominent increase in binding and 
subsequent transgene expression of Ad non-covalently coated with cationic lipids on 
differentiated airway epithelia, in vitro, as well as nasal epithelium of mice, in vivo.46 
Other researchers confirmed these findings by using cationic lipids, (proteo)- liposomes or 
cationic polymers such as poly L-lysine or polyethylenimine.46,67-72 Non-covalent coating 
offers the possibility that adenoviral infectivity is potentially retained and transduction 
efficiency elevated through increased cellular binding and uptake, while intracellular 
trafficking is not negatively influenced. As certain polycations, like linear 
polyethylenimine (LPEI), a gold standard of non-viral gene delivery systems, suffer from 
undeniable toxicity due to crosslinking of erythrocytes in the lung,73 there is a search for 
well tolerated and efficient Ad coating reagents. PAMAM dendrimers, used in this study, 
are well-known drug carriers exhibiting a considerably lower toxicity compared to LPEI 
when applied systemically,74 and having the additional advantage over LPEI to have a 
defined structure, a defined size and a defined molecular weight due to the synthesis 
procedure. The word dendrimer is derived from the Greek words dendri- (tree branch-like) 
and meros (part of). The expression was coined by Tomalia et al. in 1985 in the first full 
paper on PAMAM dendrimers.75 Dendrimers are composed of three architectural 
components: a core (I), an interior of shells with repeating branching units (II) and terminal 
functional groups (III) (Figure 6).  
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Generation Surface Groups Molecular Formula MW Diameter (nm)
2 16 C144H292N58O28 3284 2.6
3 32 C304H612N122O60 6937 3.6
5 128 C1264H2528N506O252 28854 5.7
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Figure 6. Structure, molecular weights and sizes of PAMAM dendrimers (modified from D.A. 
Tomalia, Progress in Polymer Science, 2005)76 
PAMAM dendrimers used in this study are composed of a diaminobutane core and iterative 
branches built out of methyl acrylate and ethylendiamine by iterative alkylation-amidation, with 
each generation doubling in surface groups (primary amines).  
 
Besides non-covalent coating approaches, covalent coating using hydrophilic polymers 
was investigated in order to mask surface epitopes and prevent inactivation by neutralizing 
antibodies and unwanted interactions with blood components and non-target tissue. First 
attempts were made using amine reactive polyethylene glycol (PEG), known to solubilise 
drugs and enable prolonged circulation of liposomes.77 Small PEG moieties proved to 
shield vector particles from neutralizing antibodies,78 but detargeting of Ad away from 
hepatocytes was only feasible, when large PEG moieties above 20 kDa were used 
including extensive modification of at least 10,000 amine groups of the Ad capsid.79 A 
more effective strategy in covering the sites relevant for hepatocyte transduction was 
investigated by coupling of PEG moieties to a cysteine genetically incorporated into the 
hyper variable region 5 (HVR 5) of the hexon protein. Depending on the size of the PEG 
moiety used, Ad was either detargeted from hepatocytes but taken up from KCs (2 kDa), 
evading KCs but targeted to hepatocytes (5 kDa) or detargeted from both cell types but 
also reduced in its overall infectivity (20 kDa). With this strategy higher particle 
uniformity can be gained and less polymer is needed compared to conventional amine 
PEGylation (maximum of 720 PEG moieties per viral capsid).80  
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Besides PEG, hydrophilic polymers based on N-(2-hydroxypropyl)methacrylamide 
(HPMA), bearing multiple side chains carrying amino-reactive groups at their ends are 
used for coating. Unlike PEG, HPMA is not fusogenic preventing enhanced infection 
through non-specific membrane activity.81 These polymers form a dense, multivalent 
coverage, with each polymer having several points of attachment to the virus.82 While the 
physical size of the virus is effectively unchanged, HPMA coated adenovirus is unable to 
bind to its natural receptors on target cells and shows no transduction efficiency in vitro. 
Binding of anti-adenovirus antibodies to the virus particles is reduced by about 80% by this 
coating method 82 and can be even more reduced by the use of HPMA polymers bearing 
additionally quaternary ammonium groups, which can electrostatically interact with the 
acid region of the hexon protein.83 HPMA coated virus also shows extended plasma 
circulation kinetics with a half life of over 60 min, whereas uncoated adenovirus was 
cleared from the circulation within 2 min. Along with the absence of hepatocyte infection 
and the reduction of binding to human erythrocytes,50 these coated viruses provide the 
opportunity to reach disseminated tumor sites by passive accumulation through the 
enhanced permeability and retention (EPR) effect.84 With the main advantage of stability 
of covalent versus non-covalent coated vector particles, methods have to be developed to 
increase infectivity of target cells by the addition of suitable targeting ligands.85  
While chemical modifications of oncolytic adenoviruses would only mediate targeting of 
the inoculated virus, progeny virions produced in the tumor would default to their 
genetically encoded tropism.8 Additionally, as multiple Good Manufacturing Practice 
(GMP)-grade reagents, for use in patients, have to be combined, the approach using 
chemical modification is more difficult for clinical translation, than having one genetically 
modified vector.8 On the other hand, one can argue that with the chemical modification 
approach, progeny viruses once extravasated from the tumor site would be recognized by 
the immune system, abolishing uncontrolled viral spread and infection of non-target cells. 
 
1.6.2 Targeting ligands                                                                                  
Polymer coating strategies enabling ablation of viral tropism and non specific uptake into 
tumor cells, in vivo, can be raised in their efficiency and safety profile, when adding 
targeting ligands for cancer restrictive receptors. First targeting experiments with coated 
adenoviral vectors were performed using the high affinity ligand fibroblast growth factor 2 
(FGF2),82 binding the 4 FGF receptors upregulated in a number of diseases characterized 
by hyper proliferation, including malignancies 86,87 and dermal wound healing.88  
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To date a range of internalizing receptors have been used for retargeting purposes, e.g. the 
epidermal growth factor receptor, known to be overexpressed on several cancer types and 
associated with disease progression.89 Successful EGFR retargeting ligands include murine 
EGF (mEGF)90 and Cetuximab.85 As both FGF and mEGF are potential mitogens, the 
EGFR-antibody Cetuximab, which stimulates internalization of EGFR similarly to EGF, 
but inhibits EGFR phosphorylation,85 while at the same time directing antibody dependent 
cellular toxicity,91 is a more suitable ligand for clinical use. Alternatively the peptide 
ligand GE11 (YHWYGYTPQNVI) discovered by screening a phage display library can be 
used to target the EGFR, showing much lower mitogenic activity than the natural ligand 
EGF.92 Besides EGFR targeting ligands, a laminin derived peptide (YESIKVAVS) was 
incorporated on polymer coated adenovirus to permit tumor-specific targeting via α6β1 
integrins, whose expression is upregulated during progression of prostate cancer,93 leading 
to increased migratory and invasive phenotypes.94 For all of the retargeting strategies it is 
essential, that ligands retain their biological efficacy after chemical coupling, are 
efficiently presented and accessible for target receptor binding, allow subsequent vector 
internalization and permit successful dissociation and delivery to the nucleus.16  
 
1.7 The ideal adenovirus vector  
An ideal vector would combine several characteristics, including increased circulation half 
life, prevention from scavenging by Kupffer cells and spleenic macrophages, detargeting 
from hepatocytes (either through genetically FX binding ablation or chemical capsid 
modification), protection from neutralizing antibodies, infection via disease restrictive 
receptors, additional safety through target tissue specific expression using e.g. tissue 
specific promoters or microRNA binding sites, a transgene with bystander effect like the 
sodium iodide symporter (NIS) 95 to overcome hampered spreading of oncolytic Ad within 
a solid tumor mass, while maintaining the transduction efficiency of a wild type Ad. 
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1.8 Aims of the thesis 
Adenovirus type 5 vectors (Ads) are the most commonly used vectors in cancer gene 
therapy. Despite showing high transduction efficiency in many cell types, transduction 
efficiency of cancer cells is often low due to downregulation and heterogeneous 
distribution of viral receptors. Therefore methods have to be established to increase the 
transduction efficiency of these Ad refractory cancer types.  
Non-covalent coating has been proven to enhance transduction of hardly transducable 
cancer cell lines, while highly effective, low toxicity coating agents are still being sought. 
To avoid infection of off target organs like liver and spleen, strategies have to be 
established to, not only prevent host-vector interactions and uptake of the adenovirus via 
its natural ubiquitously expressed receptors, but to target the Ad to cancer specific 
receptors. Additionally, due to high seroprevalence of neutralizing antibodies to human 
Ad5, strategies have to be developed to protect the Ad from being inactivated.  
 
The overall aim of the thesis was therefore the in vitro evaluation and optimization of non-
covalent coating strategies of adenovirus vectors for their use as gene transfer vehicles to 
solid tumors, in vivo. 
 
Specific aims: 
1) To enable high transduction efficiency in otherwise adenovirus refractory cancer 
cells, by the use of PAMAM dendrimers for non-covalent charge based coating.  
2) To characterize the shielding potency of non-covalent PAMAM dendrimer coating 
with respect to preexisting immunity. 
3) To increase specificity for cancer cells by the use of the peptide ligand GE11, 
targeting the epidermal growth factor receptor (EGFR).  
4) To evaluate the biodistribution of non-covalently coated adenovirus vectors after 
intravenous injection. 
5) To establish a SKOV-3 LucEGFP intraperitoneal mouse model, enabling an 
alternative application route to intravenous injection, and the ability of a two 
colored evaluation, using Ad-mCherry. 
 
Overall, this work should demonstrate the feasibility and potential advantages of non-
covalent adenovirus capsid modifications for in vivo tumor delivery.
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2 MATERIALS AND METHODS 
2.1 Chemicals, reagents, polymers and dendrimers 
DMSO (Dimethylsulfoxide purissimum), EtOH (absolute ethanol), DTT (DL-
Dithiothreitol) and TNBS (2,4,6-Trinitrobenzenesulfonic acid solution) were obtained from 
Sigma-Aldrich GmbH (Munich, Germany). Water was used as purified, de-ionized water. 
NHS-PEG-OPSS (ω-2-Pyridyldithio polyethylene glycol α- succinimidylester, 2 kDa) was 
synthesized by Rapp Polymere GmbH (Tübingen, Germany), peptide GE11 
(CYHWYGYTPQNVI-OH, TFA salt, >95% purity) by Biosyntan GmbH (Berlin, 
Germany), and LPEI (22 kDa) as recently described.96 Recombinant murine EGF (mEGF) 
was purchased from Peprotech (Hamburg, Germany). Amine terminated PAMAM 
dendrimers (generations G2, G3 and G5, DAB core, molecular weight  3,284 Da, 6,937 Da 
and 28,854 Da, respectively) were purchased from Dendritic Nanotechnologies (Mount 
Pleasant, MI, 48858, USA), branched PEI (BPEI, 25 kDa) was purchased from Sigma 
Aldrich and used after gelfiltration (Sephadex G25 superfine, HR 10/30) as a 1 mg/mL 
stock solution in HBS. HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) was 
obtained from Biomol GmbH (Hamburg, Germany), H-L-Cysteine from IRIS Biotech 
GmbH (Marktredwitz, Germany) and MacroPrep High S from BioRad GmbH (Munich, 
Germany). Dialysis was performed with Spectra/Por membranes (molecular mass cut-off 
1, 3.5 or 10 kDa) from Spectrum Laboratories Inc. (Breda, Netherlands). Cell culture 5x 
lysis buffer and D-luciferin sodium salt were purchased from Promega (Mannheim, 
Germany). Cell culture media, antibiotics, L-alanine-L-glutamine and non essential amino 
acids (NEAA) were obtained from Biochrom (Berlin, Germany). Fetal calf serum was 
purchased from Gibco (Life Technologies, Carlsbad, USA). 1% Phosphotungstic acid 
solution was obtained from Science Services (Munich, Germany). Carbon coated 200 mesh 
copper grids were bought from Plano GmbH (Wetzlar, Germany). Human factor X was 
purchased from Cell Cystems (Troisdorf, Germany). QIAamp DNA mini kit was bought 
from Qiagen (Hilden, Germany). Brilliant II SYBR Green qPCR Master Mix was 
purchased from Agilent Technologies (Santa Clara, USA). 
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2.1.1 Conjugate syntheses 
Conjugate syntheses and cyanine 5 labeling were performed by Wolfgang Rödl. 
Synthesis of PAMAM-PEG-OPSS 
Synthesis of PAMAM G2-PEG-OPSS was carried out in principle as described recently for 
LPEI-PEG-OPSS 97 with some modifications. In brief, 1.4 µmol of PAMAM G2 (MW = 
3284 Da) in EtOH was reacted with 4.2 µmol NHS-PEG-OPSS (2 kDa) dissolved in 
DMSO for 3 h, under agitation, at 37 °C. Thereafter, 2 M HEPES pH 7.4, 3 M NaCl and 
water were added to give a final concentration of 20 mM HEPES and 0.6 M NaCl and the 
pH adjusted to 7.4 using hydrochloric acid. The reaction mixture was loaded on a cation-
exchange column (Macro-prep High S; 10/10; BioRad, Munich, Germany) and 
fractionated with a salt gradient from 0.6 to 3 M NaCl in 20 mM HEPES, pH 7.4. The 
product eluted between 2 and 2.6 M NaCl and was dialyzed overnight (o.n.), at 4 °C, 
against HBS (20 mM HEPES pH 7.4, 150 mM NaCl). Dialysis was performed with 
Spectra/Por membrane (molecular mass cut-off 1, 3.5 or 10 kDa for PAMAM G2, G3 or 
G5 respectively). The PAMAM G2 content of the conjugate was determined by TNBS 
assay, which is used for detection of primary amines.98 Briefly 10 µL TNBS (2,4,6-
Trinitrobenzenesulfonic acid) were mixed with 320 µL Borax 0.1 M. Afterwards 1, 2, 4, 6, 
8 or 10 µL sample were pipetted into a 96-well plate in duplicate and mixed with 100 µL 
Borax and 2.5 µL of the prepared TNBS/Borax mixture. After 15 min incubation the 
absorption of the yellow product was measured at 405 nm using a microplate reader 
(Tecan, Grödig, Austria) and the amount of PAMAM G2/µL was estimated using a 
PAMAM G2 standard curve. To ascertain the quantity of linker coupled to the PAMAM 
G2, the amount of dithiopyridine (PDP) after reduction of an aliquot with dithiothreitol 
(DTT) was evaluated by spectrophotometric measurement of released pyridine-2-thione 
(ε343 = 8080 M-1 x mol-1).99 This resulted in a molar ratio of PAMAM G2/PDP of 1/0.6. 
PAMAM G3-PEG-OPSS and PAMAM G5-PEG-OPSS were synthesized with a molar 
ratio of 1/0.63 for PAMAM G3/PDP and 1/1.1 for PAMAM G5/PDP respectively. For the 
covalent coupling of PAMAM-PEG-OPSS to the Ad-Cys, new charges for all three 
generations were synthesized, with the help of Wolfgang Rödl, exhibiting a PEG-
OPSS/PAMAM ratio of 1/1.1 for PAMAM G2, 1/0.94 for PAMAM G3 and 1/0.89 for 
PAMAM G5. 
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Synthesis of PAMAM-PEG-GE11 
For PAMAM G2-PEG-GE11 synthesis, 1.98 µmol GE11 in 75 µL 30% acetonitrile, 70% 
H2O and 0.1% TFA (trifluoroacetic acid) and 0.79 µmol PAMAM G2-PEG-OPSS in 3.6 
mL HBS were mixed and incubated at ambient temperature. The reaction was considered 
to be finished once all pyridine-2-thione was released. The release was controlled during 
the reaction at 343 nm and recalculated relative to the used PDP. Purification and analysis 
was carried out, as described above, with the difference of using a salt gradient from 0.6 to 
3 M NaCl in 20 mM HEPES including 10% acetonitrile, pH 7.4. The amount of GE11 was 
calculated via the extinction coefficient at 280 nm (ε=9970 M-1 x mol-1). PAMAM G3-
PEG-GE11 and PAMAM G5-PEG-GE11 were synthesized accordingly. The molar ratio of 
PAMAM G2, PAMAM G3 and PAMAM G5 to GE11 was 1/0.75, 1/0.5 and 1/0.47 
respectively. 
 
Synthesis of PAMAM-PEG-Cys 
PAMAM G2-PEG-Cys was synthesized by mixing one part of PAMAM G2-PEG-OPSS 
with four parts of cysteine at ambient temperature. Purification was carried out on a gel-
filtration column (Sephadex G-25; HR10/30 column; 20 mM HEPES, pH 7.4) to remove 
pyridine-2-thione and unreacted cysteine. PAMAM G3-PEG-Cys and PAMAM G5-PEG-
Cys were synthesized respectively. 
 
Cyanine 5 labeling 
Cyanine 5 (Cy5) labeling of PAMAM G5 was performed with amine-reactive FluroLink 
Cy5 monofunctional dye (GE Health Care, Life Sciences, Freiburg, Germany) in principle 
as described.100 In brief, 2 mg PAMAM G5 in 1 mL HBS was mixed with 69 nmol Cy5 
dissolved in 40 µL water free DMSO. After 2 h at ambient temperature the sample was 
purified by gel filtration to remove unreacted dye. The molar ratio of PAMAM G5/Cy5 
was 1/0.3.  
 
2.2 Antibodies 
Goat anti-human IgG-peroxidase antibody was bought from Sigma-Aldrich (St. Louis, 
USA). Mouse anti-human CAR antibody (clone RmcB) was obtained from Millipore 
(Schwalbach, Germany). Mouse anti-human transferrin receptor, mouse anti-human 
epidermal growth factor receptor (clone H11) and mouse IgG control antibody were 
purchased from Dako (Copenhagen, Denmark). Mouse anti-human CD51/61 (αvβ3 integrin) 
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was purchased from Biolegend (San Diego, USA). Goat anti-human Alexa 488 and goat 
anti-human Alexa 647 antibody were obtained from Invitrogen (Eugene, USA). Privigen®, 
human anti-Ad IgG was bought from CSL Behring (Marburg, Germany). 
 
2.3 Adenovirus vectors 
Ad-Luc [1x1010 viral particles per microliter (VP/µL)], 5x108 plaque-forming units per 
microliter (PFU/µL) was purchased from Vector Biolabs (Philadelphia, PA 19104, USA) 
and amplified in HEK 293 cells in the lab of Per Holm. The virus was purified by two 
consecutive, continuous cesium chloride (CsCl) gradient centrifugations and desalted by 
size-exclusion chromatography (Disposable PD-10 desalting columns, GE Healthcare, 
Munich, Germany). Viral titer was determined by AdEasy™ Viral Titer Kit (Stratagene, 
Waldbronn, Germany) and viral particle number by absorption measurement at 260 nm. 
Ad-Alexa Fluor488 (Ad-Alexa488, 1x108 VP/µL, 5x106 PFU/µL), enhanced green 
fluorescent protein encoding Ad (Ad-EGFP, 5x108 VP/µL, 1x108 PFU/µL), enhanced 
green fluorescent and luciferase fusion protein encoding Ad (Ad-EGFPLuc, 1x109 VP/µL, 
6x107 PFU/µL) and mCherry encoding Ad (Ad-mCherry, 1x109 VP/µL, 5x10 8 PFU/µL) 
are Ad5-based E1-deleted first-generation vectors. All were amplified in the E1-
transcomplementing N52E6 cell line in the lab of Florian Kreppel.101 The Ad-EGFP and 
Ad-EGFPLuc carry a hCMV-promoter controlled EGFP or EGFPLuc expression cassette 
respectively, whereas the Ad-mCherry carries an EF1α-promotor controlled mCherry 
expression cassette. Vectors were purified by one CsCl density step gradient followed by 
one subsequent continuous CsCl density gradient and were desalted by PD-10 size 
exclusion columns (GE Healthcare). The titers for infectious and physical particles were 
determined by a DNA-based slot blot assay 102 and the physical particle titer was 
confirmed by measuring the optical density at 260 nm. Ad-CMV-hNIS 103 (Ad-NIS) 
(1.1x109 VP/µL, 5x107 PFU/µL) was prepared by Richard D. Anderson from ViraQuest 
Inc. (North Liberty, USA). 
 
Alexa 488 labeling 
For random labeling, 5x1011 AdEmpty (no transgene) vector particles were incubated with 
a 20-fold excess of amine reactive Alexa Fluor488-5TFP (Invitrogen, Darmstadt, 
Germany) over the 18,000 amino groups present at the capsid surface. After incubating 
over night, at ambient temperature, the reaction mixture was made up to a final volume of 
2.5 mL with PBS. The labeled vector particles were then purified from excess dye by 
PD10 column purification (GE Healthcare).  
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2.4 Coating of Ad with PAMAM dendrimers or LPEI and BPEI polymers 
The complexes of Ad and PAMAM generation 2, 3, 5, LPEI or BPEI were formed (unless 
otherwise stated) by separately diluting the indicated amounts of Ad in Opti-MEM® 
(Invitrogen, Darmstadt, Germany) and polycation in HEPES buffered Glucose (HBG; 
20mM HEPES, 5% glucose, pH 7.4). Viral particles were added to the polycation solution, 
immediately gently mixed with a pipette and allowed to incubate for 30 min at ambient 
temperature (20 -25 °C) before further use. 
 
2.5 Biophysical Characterization 
2.5.1 Transmission electron microscopy (TEM) 
Sample preparation was performed similar to the method shown by Chen et al. 104 with 
some modifications. A 20 µL drop containing either 1x1010 VP of Ad-Luc in water or Ad 
complexed with 455 ng PAMAM G5 in PBS, which equals 950 molecules per adenovirus, 
was put on a sheet of parafilm. A plasma cleaned carbon coated 200 mesh copper grid 
(Plano GmbH, Wetzlar, Germany) was placed on top of the drop (filmed side down) for 5 
min and excess liquid was blotted off using filter paper. Subsequently the grid was 
incubated with 20 µL of a 1% phosphotungstic acid solution (PTA) (Science Services, 
Munich, Germany) for 3 min and drained as before. All solvents were filtered with a 0.02 
µm spin column filter (Whatman, Dassel, Germany) before use. Air dried grids were 
analyzed within 48 h by Kulpreet Virdi using a JEOL 2011 TEM (JEOL Ltd. Tokyo, 
Japan) fitted with a lanthanum hexaboride thermal emitter and operating at an accelerating 
voltage of 200 kV and at low dose. 
 
2.5.2 Zeta potential and particle size measurement 
Ad-Luc (5x1010 VP/mL in PBS/HBG, pH 7.4) and Ad/PAMAM G5 complexes (formed as 
described in 2.4, but with Ad diluted in PBS instead of Opti-MEM® to reduce background 
signal) were analyzed on a Zetasizer Nano ZS (Malvern Instruments, Malvern Hills, UK) 
at 25 °C in triplicates for measurement of the zeta potential. Size measurement of Ad-
EGFP, Ad-NIS and Ad-Luc only or coated with PAMAM G5 was performed by photon 
correlation spectroscopy (PCS). Measurements were conducted on a Coulter N4 Plus 
(Beckman Coulter, Brea, USA) with 90° angle PSC analysis using 2x1011 VP or 1x1011 VP 
respectively in a total volume of 2 mL PBS/HBG mixture. 
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2.5.3 Gel electrophoresis and silver staining 
To analyze the purity of different Ad preparations gel electrophoresis followed by silver 
staining was performed. 5x109 VP of Ad-EGFP, Ad-NIS and Ad-Luc were mixed with 2x 
loading buffer (0.2% bromophenol blue, 200 mM DTT, 20% glycerine, 4% SDS, 100 mM 
Tris HCl, pH 6.8) and denatured for 2 min at 96 °C. Gel electrophoresis was performed at 
120 V for 1.5 h using a 3.5% stacking and a 10% resolving gel. The gel was fixed with a 
fixative solution (50% methanol, 12% acetic acid, 0.5mL/L 37% formaldehyde solution) 
o.n. at 4 °C. After pretreatment with sodium thiosulfate solution (127 mg/L) for 1 min, the 
gel was incubated with a silver nitrate solution (silver nitrate 2 g/L, 0.5 mL/L 37% 
formaldehyde solution) for 20 min. Formaldehyde containing developer solution (0.5 mL/L 
37% formaldehyde, 60 g/L sodium carbonate, 2.5 mg/L sodium thiosulfate) was used to 
reduce silver ions to metallic silver and the reaction was stopped by addition of 12% acetic 
acid in 50% methanol for 5 min. 
 
2.6 Biological characterization 
2.6.1 Cell culture 
Human cancer cell lines were maintained as follows. HuH7 hepatoma cells (JCRB0403; 
Japanese Cancer Research Resources Bank, Tokyo, Japan) were cultivated in Ham’s 
F12/DMEM (1:1), SKOV-3 ovarian carcinoma cells (HTB-77; American Type Culture 
Collection [ATCC], Manassas, VA), SKOV-3 LucEGFP stably transfected cells (kindly 
provided by Izumi Ohno, laboratory of Nori Kasahara) HepG2 hepatoma cells (HB-8065, 
ATCC) and DU145 prostate carcinoma cells (ACC 261; German Collection of 
Microorganisms and Cell Culture [DSMZ], Braunschweig, Germany) in RPMI 1640, A549 
lung carcinoma cells (CCL-185, ATCC) and U87MG glioblastoma cells (HTB-14, ATCC) 
in DMEM. All cell culture media were supplemented with 10% fetal bovine serum, 100 
units/mL penicillin, 100 µg/mL streptomycin and 1% L-Alanine-L-Glutamine (200 mM). 
Medium for U87MG cells was additionally supplemented with 1% NEAA (non-essential 
amino acids) and cell culture flasks where coated with 0.1 mg/mL Collagen A before use. 
All cells were passaged twice a week and cultured at 37 °C in 5% CO2. 
 
2.6.2 Receptor level estimation 
Cells, 6x105 in 100 µL FACS buffer (10% FCS in PBS), were incubated with either mouse 
anti-CAR, mouse anti-EGFR, mouse anti-TfR, mouse anti-CD51/61 (1:200 dilution) or 
mouse IgG control antibody (1:100 dilution) for 1.5 h on ice and then washed twice with 
FACS buffer. Thereafter cell were stained with Alexa-488-labeled goat anti-mouse    
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(1:400 dilution) or Alexa-647-labeled goat anti-mouse (1:200 dilution) secondary antibody 
for 1 h on ice, washed, counterstained with DAPI (1 µg/mL) and analyzed on a Cyan ADP 
flow cytometer (Dako, Glostrup, Denmark). DAPI fluorescence was excited at 405 nm and 
detected with a 450/50 bandpass filter, Alexa-488 fluorescence was excited at 488 nm and 
detected with a 530/40 nm bandpass and Alexa-647 fluorescence was excited at 635 nm 
and emission was detected with a 665/20 nm bandpass filter. 4x104 events (living cells) 
were collected per sample, using forward scatter (FS) versus sideward scatter (SS) to 
exclude cell debris and apoptotic cells, FS versus pulse width to exclude duplets and FS 
versus violet one channel to exclude necrotic cells.  The percentage of CAR and EGFR 
positive cells was determined compared to control IgG stained cells. The mean 
fluorescence intensity (MFI) corresponds to the arithmetic mean of the living cell 
population.   
 
2.6.3 Cellular uptake and co-localization studies  
For flow cytometry analyses, 5x104 cells were seeded in 24-well plates 24 h prior to 
transduction. On the day of transduction cells were 70-80% confluent. Medium was 
removed and 250 µL of Opti-MEM® containing Ad-Alexa488 only (10,000 VP/cell, MOI 
500) or complexed with various amounts of PAMAM G5-Cy5 dendrimer were incubated 
with cells for 2 h, at 37 °C, and in 5% CO2. Thereafter the cells were washed twice with 
PBS, harvested with Trypsin/EDTA, fixed with 2% paraformaldehyde (PFA) for 30 min at 
ambient temperature and analyzed by flow cytometry as described above using a FACS 
Canto II flow cytometer (Becton, Dickinson, Germany) (Alexa 488: excitation at 488 nm, 
emission at 530/30 bandpass, Cy5: excitation at 633 nm, emission at 660/20 bandpass).  
For laser scanning microscopy (LSM) studies, 2x104 cells were seeded in Collagen A (0.1 
mg/mL) coated LabtekTM chamber slides, 24 h prior to transduction. PAMAM or LPEI 
coated Ad was incubated with cells for 2 h at 37 °C, thereafter cells were washed three 
times with PBS and fixed with 4% PFA for 30 min. Nuclei were stained using DAPI (1 
µg/mL). Samples were analyzed with a confocal laser scanning microscope (LSM 510 
META; Carl Zeiss, Jena, Germany) equipped with an argon laser emitting ultraviolet light 
at 364 nm, a second argon laser emitting light at 488 nm and two helium/neon lasers 
delivering light at 543 nm and 633 nm. A 63x oil immersion objective (Carl Zeiss) was 
used and data acquisition done in multitrack mode (DAPI: excitation at 364 nm, emission 
at 385-470 nm bandpass, Alexa 488: excitation at 488 nm, emission at 505-530 nm 
bandpass, Cy5: excitation at 633 nm, emission at 650 nm longpass). The data was analyzed 
with AxioVision 4.6 software (Carl Zeiss). 
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2.6.4 Transduction studies 
Cells were seeded at a density of 1x104 cells/well in 96-well plates 24 h prior to 
transduction and were 70-80% confluent on the day of transduction. The medium was 
removed and 60 µL of serum free Opti-MEM® (or up to 100% FCS in DMEM for stability 
studies) containing Ad-Luc or Ad-EGFPLuc (MOI 100) alone or complexed with various 
amounts of dendrimer or polymer were incubated with cells for 2 h (or 45 min for EGFR-
targeting experiments) at 37 °C. To show the specificity of PAMAM G2-PEG-GE11, cells 
were pre-incubated with 10 µg/well mEGF for 45 min at 37 °C. DNA/PAMAM polyplexes 
were also formed within 30 min at RT and incubated with cells for 2 h at 37 °C 
accordingly. The infection solution was replaced by fresh serum-containing medium and 
after 48 h cells were lysed using 5x cell lysis buffer in a 1:10 dilution. Luciferase activity 
of a 35 µl aliquot was quantified on a Centro LB 960 luminometer (Berthold Technologies, 
Bad Wildbad, Germany).74 Two nanograms of recombinant luciferase correspond to 1x107 
relative light units (RLU).  
 
2.6.5 Cell viability assay (MTT)    
The influence on cell metabolism of the Ad/PAMAM, Ad/LPEI and Ad/BPEI complexes 
was evaluated using a MTT colorimetric assay. 10 µL of MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide, 5mg/mL] were added to the cells, 48 h after 
transduction and incubated for 2 h at 37 °C. Thereafter the supernatant was removed and 
the plate kept at -80°C for 30 min. The purple formazan crystals were dissolved in 100 
µL/well dimethyl sulfoxide (DMSO). Absorbance was measured at 590 nm with 
background correction at 630 nm using a microplate reader (Tecan, Grödig, Austria). The 
relative cell viability (in %) was calculated by [A] sample /[A] control x 100. 
 
2.6.6 Neutralization assay 
A549 cells were seeded at a density of 5x104 cells/well in 24-well plates 24 h prior to 
transduction. On the day of transduction cells were 70-80% confluent. Complexes of Ad-
EGFP and dendrimer were pre-formed at ambient temperature for 30 min. Thereafter, 50 
µL Ad or Ad/PAMAM G5 containing 2.5x107 VP were mixed with 10 µL diluted human 
IgG containing anti-Ad antibodies (Privigen®, CSL Behring, Marburg, Germany) and 
incubated for a further 30 min; the final IgG concentration was in the range of 0.08-3.3 
mg/mL. Cells were transduced with a MOI of 100, under serum free conditions, in a total 
volume of 250 µL in Opti-MEM®. After incubating for 2 h, 1 mL fresh serum-containing 
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medium was added and the medium replaced after 24 h. After 48 h, the cells were analyzed 
for EGFP expression by flow cytometry collecting 2x104 gated events per sample. 
 
2.6.7 ELISA 
For the indirect ELISA, 6x1010 viral particles (VP) were heat-inactivated for 10 min at 60 
°C. A volume of 50 µL/well containing 6x108 of these VP in coating buffer (0.2M 
Na2CO3/NaHCO3 pH 9.5) were added to a 96-well maxisorb flat bottom plate (Nunc, 
Thermo Scientific Fisher, Schwerte, Germany) and incubated o.n. at 4 °C with gently 
agitation. The coated wells were then blocked with 3% BSA in PBS for 1 h at RT. Human 
IgG (Privigen®, 100 mg/mL) was diluted gradually 1:2 starting from a 1:250 dilution. In 
order to prove that there was no interaction between PAMAM and anti-Ad IgG, the 
Privigen® dilutions were pre-incubated with 100 ng PAMAM dendrimer or HBG, as 
control, for 30 min, before application to the immobilized Ad, for 2 h at RT. A 1:2000 
dilution of a peroxidise anti-human IgG antibody was added for 1 h at RT before the 
addition of o-phenylendiamine dihydrochloride containing substrate solution, pH 5, for 5 
min. The colour reaction was stopped by adding 1M H2SO4 and the absorbance measured 
at 485 nm with background correction at 630 nm, using a microplate reader. 
 
2.6.8 Factor X binding assay 
SKOV-3 cells were seeded at a density of 2x104 cells/well in 96-well plates 24 h prior to 
transduction. On the day of transduction cells had reached 70-80% of confluency. Cells 
were washed once with PBS and additive-free medium or medium containing factor X at a 
physiological concentration (8 µg/mL) was applied. Naked Ad versus Ad/PAMAM was 
added at a particle MOI (pMOI) of 1000 and incubated with cells for 3 h at 37 °C. After 
transduction, cells were washed once with PBS before adding fresh growth medium 
supplemented with 10% FCS, 1% stable glutamine and 1% penicillin/streptomycin. After 
72 h the cells were analyzed for EGFP expression using FACS with 2x104 gated events per 
sample.  
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2.6.9 Targeting studies 
For targeting studies 5x104 cells were seeded in 24-well plates 24 h prior to transduction 
and were transduced with Ad-EGFP alone or coated with PAMAM G2-PEG-GE11 or 
PAMAM G2-PEG-Cys at a MOI of 100 under serum-free conditions in a total volume of 
250 µL. After 45 min incubation at 37 °C the solution was replaced by 1 mL fresh serum-
containing medium. After 48 h, cells where harvested and 2x104 gated cells were analyzed 
for EGFP expression using flow cytometry. 
For LSM imaging 2x104 cells, seeded in Collagen A-coated chamber slides, were treated 
accordingly and after 48 h fixed with 4% PFA for 30 min before evaluation by laser 
scanning microscopy, as described earlier.  
 
2.7 In vivo experiments on biodistribution 
For studies on biodistribution of Ad versus Ad/PAMAM G5 female BALB/cAnNCrl 
(BALB/c) mice were used. Mice were obtained from Charles River (Sulzfeld, Germany) 
and maintained in pathogen-free, individually ventilated cages (Tecniplast, 
Hohenpeissenberg, Germany) in the animal facility of PD Dr. Florian Kreppel and Prof. 
Dr. Stefan Kochanek at the University of Ulm. Mice were fed with sterilized diet for 
laboratory rodents (Ssniff, Soest, Germany) and experiments started, when mice were 6-8 
weeks old. Animal experiments were approved by the Animal Care Commission of the 
Government of Baden-Württemberg and were in accordance with institutional guidelines. 
3x1010 VP of an EGFP encoding Ad, with or without PAMAM coating (250 ng or 1500 
ng), were injected intravenously by Matthias Kron into the tail vein of mice in a total 
volume of 200 µL PBS/HBG 1:1 mixture. For comparative studies, two different mouse 
strains, female BALB/cAnCrl and CD1 nu/nu mice were selected, obtained from Charles 
River (Sulzfeld, Germany) and maintained under specific pathogen-free conditions in 
individually ventilated cages at the animal facility of the Klinikum rechts der Isar (Munich, 
Germany). Mice had access to sterilized diet for laboratory rodents and water, ad libitum. 
Experiments started, when mice were 5-7 weeks old. Then 2.2x1010 VP of an EGFP 
encoding Ad, with or without PAMAM coating (300 ng), was injected intravenously, by 
Geoffrey Grünwald, into the tail vein of mice, in a total volume of 200 µL Opti-
MEM/HBG 1:1 mixture.  The experimental protocol was in accordance with institutional 
guidelines and approved by the regional governmental commission for animals (Regierung 
von Oberbayern, Munich, Germany). 72 h after injection, mice were sacrificed by an 
overdose of isoflurane (Abott, Ludwigshafen, Germany) inhalation and the liver (after 
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perfusion with PBS), lung, kidney and spleen were taken out. One piece of each organ was 
fixed for 24 h in 2% PFA followed by 24 h in 30% sucrose and embedding in Tissue-Tek® 
for histological sections; one piece was snap-frozen in liquid nitrogen and stored at -80°C 
for DNA isolation and in the case of the liver a second piece was snap-frozen and used for 
homogenization.  
 
2.7.1 Fluorometry of liver homogenates 
After PBS perfusion and snap freezing in liquid nitrogen, 0.5 g of each mouse liver was 
homogenized in a conical tissue grinder (Wheaton, Millville, NJ) using 1 ml RIPA buffer 
[50 mM Tris, 1% NP-40, 0.25% sodium desoxycholate, 150 mM NaCl, 1 mM EDTA, 1 
mM phenylmethylsulfonyl fluoride (PMSF), ad 1 L with demineralized water, pH 7.4] and 
incubated for 10 min at RT. After centrifugation at 20,000 g for 10 min at 4 °C, 500 µL of 
the clear supernatant fraction were transferred into a new 1.5 mL reaction tube. 
Centrifugation was repeated, as described above, and 200 µL of the clear supernatant 
fraction was removed and diluted 1:500 in RIPA buffer before measurement of the EGFP 
fluorescence at 488 nm excitation and 512 nm emission wavelength with a LS50B 
spectrometer (Perkin Elmer, Waltham, USA) and the Spex dM300 software version 3.32e 
(SPEX instruments SA. Inc, NJ, USA). 
 
2.7.2 Cryosections 
A piece of liver, lung, spleen and kidney was fixed o.n. in 2% PFA, followed by an o.n. 
incubation in 30% sucrose before embedding in Tissue-Tek® (Sakura, Zoeterwoude, 
Netherlands) and storing at -80 °C. 6 µm sections were cut using a Leica CM3050S-
cryostat (Leica Biosystems, Wetzlar, Germany). Sections were put on microscope slides, 
covered with fluorescent mounting medium (Dako, Copenhagen, Denmark) and analyzed 
with a confocal laser scanning microscope (LSM 510 META; Carl Zeiss, Jena, Germany). 
 
2.7.3 Quantitative real time PCR (qPCR) 
DNA isolation from mice tissue was undertaken using the QIAamp DNA mini kit (Qiagen) 
according to the manufacturer’s protocol. Additionally an ethanol precipitation was 
performed to increase purity of the samples. QPCR was carried out by amplification of the 
Ad E4 gene with a Stratagene 3005P qPCR machine and the MxPro MX3005P v4.01 
software using 2x Brilliant II SYBR® Green qPCR Master Mix and the following primers: 
E4 sense (5`-TAGACGATCCCTACTGTACG-3′), E4 anti-sense (5`-
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GGAAATATGACTACGTCCGG-3′), as well as murine β-actin-sense (5′-
CAAGGAGTGCAAGAACACAG-3′) and murine β-actin-antisense (5′-
GCCTTGGAGTGTGTATTGAG-3′) for later normalization for cellular DNA content. 
Forty cycles with the following thermal protocol were performed: melting (95 °C, 30 sec) 
annealing (60 °C, 30 sec) and elongation (72 °C, 20 sec). Samples were run in duplicate 
and the averaged CT values for the E4 adenoviral gene were normalized against the β-actin 
CT values of the same sample. On every plate β-actin standard ranging from 1x100 to 1x105 
copies and an E4 standard ranging from 1x10-1 to 1x104 copies was run in parallel. Copy 
numbers of Ad/cell were calculated using the E4 standard equation. 
 
2.8 Establishment of a SKOV-3 intraperitoneal cancer mouse model 
2.8.1 In vitro characterization of SKOV-3 LucEGFP cells 
2.8.1.1  Quantification of the luciferase and EGFP expression level 
To quantify the luciferase expression level of SKOV-3 LucEGFP cells, 2,000, 5,000 and 
10,000 cells/well (n=6) were seeded in a 96-well plate. After 24 h the cells were lysed and 
a luciferase assay was performed, as described earlier. The EGFP expression level was 
analyzed by FACS for mean fluorescence intensity (MFI) in the FITC channel as well as 
percentage of EGFP positive cells performing diagonal gating of FITC versus PE-Texas 
Red. A549 cells were used as control for laser adjustment. 
 
2.8.1.2  Receptor level estimation 
Receptor level estimation was performed as described in 2.6.2, using an Alexa 647 labeled 
secondary antibody (1:200 dilution). 
 
2.8.2 Establishment of a dual color system 
2.8.2.1  Cloning of Ad-mCherry 
For cloning of the mCherry construct, 1 µg of pCpG-hCMV EF1α-TNF and pCpG-hCMV 
SCEP-mCherry, cloned by Rudolf Haase, were digested for 2 h at 37 °C using 0.3 µL 
HindIII and SpeI-HF enzyme [New England Biolabs GmbH (NEB), Frankfurt am Main, 
Germany] in a final volume of 20 µL. Digestion products were separated on a 2% agarose 
gel at 80-100 mV and gel extraction performed according to the QIAquick gel extraction 
kit (Qiagen, Hilden, Germany). Ligation of the EF1α-promotor with the mCherry 
containing backbone was performed in a molar ratio of 1:3 (vector: insert) with 0.5 µL T4 
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DNA ligase (NEB) in a volume of 10 µL for 1 h at 30 °C. Transformation via heat shock at 
42 °C for 1 min and 45 sec, with pre and post incubation on ice for 2 min, was performed 
with DB 3.1 chemo competent cells prepared by Ursula Biebl. Afterwards 1 mL of LB 
medium was added and the bacteria were incubated at 37 °C for 1.5 h under continuous 
agitation (350 rpm). Afterwards the bacteria were centrifuged for 6 min at 6000 rpm. 
Bacterial pellet was resuspended in 100 µL LB, spread on Zeocin (25 µg/mL) (Roche, 
Mannheim, Germany) or Ampicillin (100 µg/mL ) plates (1.5% agar in LB medium) and 
incubated at 37 °C o.n. for clonal selection. Plasmid preparation was carried out using a 
QIAprep Spin Miniprep Kit (Qiagen) according to the manufacturer’s instructions. To 
verify the insertion of the EF1α promoter, the plasmid was cut with the restriction enzymes 
SmlI and NheI. The pCpG-hCMV EF1α-mCherry construct was additionally verified by 
sequencing, employing GATC Biotech (Constance, Germany). In the final step, performed 
by Sandra Behmüller, the pCpG-hCMV EF1α-mCherry was digested with PacI (NEB) o.n 
as was the pGs66 101 backbone. Separation was performed using a 1% agarose gel at 100-
120 mV. Bands were cut out using a dark reader and equivalent goggles. After phenol 
extraction and precipitation with isopropanol and ethanol, ligation was performed o.n. at 
RT. Therefore vector and insert were separately heated up to 42 °C for 20 min, before 
pipetting the ligation mix on ice. Transformation was performed by electroporation using 
XL2-blue ultracompetent cells (Stratagene, La Jolla, USA). 
 
2.8.2.2  Transduction of SKOV-3 LucEGFP using Ad-mCherry  
For LSM and FACS analysis 2.5x104 SKOV-3 LucEGFP were seeded in 24-well plates 
and transduced with Ad (MOI 125) only or coated with PAMAM generation 2, 3, 5 or the 
respective targeting and control constructs PAMAM-PEG-GE11 and PAMAM-PEG-Cys 
of each generation for 2 h at 37 °C. FACS analysis was carried out with an excitation at 
488 nm for EGFP and mCherry, while use of different filters (530/40 nm for EGFP; 680/30 
nm for mCherry) allowed for separate detection of the two fluorophores. 2x104 gated cells 
were analyzed. LSM was performed using a 488 nm argon laser for excitation of EGFP 
and a 543 nm helium-neon laser for excitation of mCherry, while using a 505-530 nm band 
pass and 560 nm long pass filter respectively for detection. 
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2.8.3 In vivo characterization of SKOV-3 LucEGFP cells 
2.8.3.1  Luciferase imaging  
Luciferase imaging of Rj:NMRI-nu (nu/nu) mice (Janvier, Le Genest-St-Isle, France) 
carrying intraperitoneally (i.p.) implanted SKOV-3 LucEGFP tumors was performed twice 
a week using an IVIS Lumina imaging system and the Living Image software 3.2 (Caliper 
Life Sciences, Hopkinton, USA). Mice were anesthetized with 3% isoflurane in oxygen, 
100 µL luciferin solution (c=60 mg/mL, in PBS) (Promega, Fitchburg, USA) was injected 
i.p. and light efflux recorded after 10 min, with an acquisition time of 2 sec. For 
quantification of the bioluminescent signal, a region of interest (ROI) was adjusted to the 
abdominal cavity and the signal measured as emitted photons/sec.  
 
2.8.3.2  Hematoxylin and eosin staining 
Organs were fixed with 4% PFA, embedded in paraffin, cut in 5 µm sections and mounted 
on microscopic slides. Hematoxylin and eosin staining of liver, spleen, stomach and small 
intestine was performed by Alke Schropp according to a standard protocol. Briefly, slides 
were immersed in xylene for 15 min, twice, followed by absolute EtOH, 96% EtOH and 
70% EtOH for 5 min each. After a brief rinse in distilled water, slides were stained with 
hematoxylin (Merck, Darmstadt, Germany) for 5-30 sec, rinsed with tap water for 10 min 
and stained with eosin (Chroma, Münster, Germany) for 10 min. Thereafter slides were 
rinsed with tap water for 3 min and immersed in 70% EtOH and 96% EtOH for 3 min and 
absolute EtOH for 5 min. Before embedding in Eukitt® (O. Kindler GmbH & Co, Freiburg, 
Germany), slides were immersed in xylene for 10 min, twice. Images of H/E staining were 
taken with an Olympus BX41 microscope using an Olympus DP25 U-TV1X-2 camera and 
the Olympus cellSensEntry 1.5 software (Olympus, Hamburg, Germany) in the group of 
Prof. Dr. Angelika Vollmar. 
 
2.9 Statistical analysis 
Results are presented as mean ± standard deviation. Statistical significance was evaluated 
by an unpaired two tailed t-test using Graph Pad Prism 6.0. P-values < 0.05 were 
considered significant. 
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3 RESULTS 
3.1 Biophysical characterization of Ad and Ad/PAMAM complexes 
For the in vitro evaluation and optimization of non-covalent coating strategies of Ad vectors 
using PAMAM dendrimers, complexes were first characterized biophysically, starting with 
transmission electron microscopy (TEM) studies. 
 
3.1.1 Coating efficiency shown by transmission electron microscopy 
The structure of uncoated Ad (Ad-Luc) and Ad/PAMAM G5 complexes was analyzed by 
transmission electron microscopy (TEM) using phosphotungstic acid (PTA) stained 
samples (Figure 7). Uncoated Ad capsids displayed the characteristic hexon structure as 
well as the icosahedral shape of the adenoviral particle. In contrast, when coated with 455 
ng PAMAM G5 (equals 950 molecules/Ad) capsids revealed a rough surface structure, 
indicating complete coating of the Ad particles. In general, single coated particles were 
observed, but also smaller numbers of dimers or moderate numbers of aggregates, similar 
to uncoated Ad, occurred.  
 
 
A
 
Figure 7. TEM images of uncoated versus PAMAM G5 coated Ad 
(A) Transmission electron micrographs of PTA stained Ad (top row) and Ad/PAMAM G5 
complexes (bottom row); magnification: A and D 40,000x, B and E 30,000x, C and F 25,000x; 
scale bars: 100 nm. Representative images are shown. 
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To identify the amount of PAMAM, that is needed to show complete coating in TEM 
images, also 100 ng (equals 208 molecules/Ad) and 10 ng (equals 21 molecules/Ad) were 
tested (Figure 8). While coating with 100 ng PAMAM G5 still led to fully coated 
Ad/PAMAM particles, coating with 10 ng produced around 50% of uncoated complexes. 
 
A B
C D
 
Figure 8. TEM images of 10 ng versus 100 ng PAMAM G5 coated Ad 
(A) Transmission electron micrographs of PTA stained Ad/PAMAM G5 10 ng (top row) and 
Ad/PAMAM G5 100 ng (bottom row); magnification: A and C 15,000x, B and D 6,000x. White 
arrows depict examples of uncoated Ad. Representative images are shown. 
 
3.1.2 Zeta potential measurement 
For measuring the surface charge, 5x1010 viral particles (VP) in PBS were coated with 
indicated amounts of PAMAM G5 diluted in HBG. Uncoated Ad exhibited a negative 
surface charge with a zeta potential corresponding to -17.4 ± 1.6 mV. In sharp contrast, a 
zeta potential corresponding to +3.4 ± 0.7 mV was measured, when Ad was coated by 20 
µg PAMAM G5 (Figure 9). 
 
 
 
 
 
Results     30 
 
-20
-15
-10
-5
0
5
-5 0 5 10 15 20
Adenovirus only
■ Adenovirus + PAMAM G5Ze
ta
po
te
n
tia
l (m
V)
µg PAMAM G5
 
Figure 9. Zeta potential measurement of uncoated versus PAMAM G5 coated Ad 
Zeta potential of Ad versus Ad/PAMAM G5 complexes was measured by laser doppler micro-
electrophoresis using a Zetasizer Nano ZS and 5x1010 VP in 1 mL solvent plus the indicated 
amounts of PAMAM G5 dendrimer. Triple measurements of one sample ± variation of the median 
are shown. 
 
3.1.3 Size measurement 
For measurement of the size of the uncoated Ad compared to the Ad/PAMAM G5 
complexes two experiments were taken into account. Representative images gained by 
TEM were analyzed with the Gatan Digital Micrograph software (Figure 10). Capsid 
diameters of 70-83 nm were measured for uncoated Ad (A, B) and 143-160 nm for 
PAMAM G5 coated Ad (C, D) revealing a doubling in size after coating with 455 ng 
PAMAM G5 (equals 950 molecules/Ad). 
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Figure 10. Size of Ad and PAMAM G5 coated Ad measured by TEM  
(A-F) Electron micrographs of PTA stained Ad (A, B) and Ad/PAMAM G5 complexes (C, D) 
were analyzed with Gatan Digital Micrograph software (Gatan Inc., Pleasanton, California). 
Background staining is displayed for water alone (E) and PAMAM G5 dendrimer in PBS (F). 
magnification: A and C 40,000x, B, D, E and F 30,000x; scale bars: 100 nm. Representative images 
are shown. 
 
Additionally, size measurement by dynamic light scattering (DLS), using a Beckman–
Coulter N4Plus, was performed (Figure 11B). DSL measures the Brownian motion relative 
to the hydrodynamic diameter of the particles. The smaller the particles the higher the 
Brownian motion, measured by a higher fluctuation rate of the intensity of the scattered 
light. 2x1011 VP Ad-EGFP, Ad-NIS or Ad-Luc were prepared in 2 mL PBS. After the sizes 
of the VP were measured, samples were separated into two parts and mixed with PAMAM 
G5 (958 ng and 4791 ng) diluted in HBG, referring to 200 and 1000 molecules PAMAM 
G5/Ad respectively. For the Ad-EGFP from the lab of Florian Kreppel a high sample 
uniformity with a poly dispersity index (PDI) of only 0.04 and a size of 118 ± 28 nm could 
be found. For the Ad-NIS a PDI of 0.07 and a size of 115 ± 37 nm were measured and for 
the Ad-Luc a PDI of 0.44 and a size of 145 ± 63 nm was found. Whereas the Ad-EGFP 
revealed a homogeneous size distribution after coating, in all 3 rounds of measurement, 
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Ad-NIS as well as Ad-Luc showed several peaks after coating with 200 PAMAM G5 
molecules/Ad and a broader size distribution, when coated with 1000 PAMAM G5 
molecules/Ad as illustrated in the intensity profiles depicted in figure 11A. 
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Ad sample PG5/Ad Solvent PDI Size [nm]
Ad-EGFP 0 PBS 0.04 118 ± 28
Ad-EGFP 200 PBS/HBG 0.14 168 ± 61
Ad-EGFP 1000 PBS/HBG 0.41 1128 ± 490
Ad-NIS 0 PBS 0.07 115 ± 37
Ad-NIS 200 PBS/HBG 0.35 231 ± 99
Ad-NIS 1000 PBS/HBG 0.41 1010 ± 374
Ad-Luc 0 PBS 0.44 145 ± 63
Ad-Luc 200 PBS/HBG 0.59 264 ± 120
Ad-Luc 1000 PBS/HBG 0.22 862 ± 298
B
 
Figure 11. Size of Ad and PAMAM G5 (PG5) coated Ad measured by dynamic light scattering  
Size measurement of 2x1011 VP of Ad-EGFP, Ad-NIS or Ad-Luc only in 2 mL solvent or 1x1011 
VP plus the indicated amount of molecules PAMAM G5/Ad. (A) Intensity profiles, showing the 
size distribution as well as the occurrence of each size in % intensity. (B) Results on size 
measurement as well as poly dispersity index (PDI) for each Ad preparation gained as unimodal 
results from the PCS Control Software Version 2.02 (Beckman Coulter). Triplicate measurements 
of one sample ± variation of the median are shown. 
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3.2 Comparing purity of different adenovirus preparations 
When considering a non-covalent coating approach based on charge interaction, it is of 
importance to have a pure virus preparation uncontaminated by cellular proteins, which 
might interfere with the coating process. Therefore three different adenovirus preparations 
from three different laboratories were compared using a silver staining technique (Figure 
12). When 5x109 VP of Ad-EGFP or Ad-NIS were used, a characteristic band pattern was 
seen, where the 108 kDa hexon band was the highest molecular weight band and with 720 
copies was the most prominent band. Only when higher concentrations were used (1x1010 
VP), impurities above the hexon band did occur for Ad-NIS. Contrary to this, Ad-Luc 
showed impurities around 60 kDa and above 100 kDa with 5x109 VP. This later led to the 
exchange of the Ad-Luc, which was purified by two continuous density gradients against 
Ad-EGFPLuc, which was purified by one density step gradient followed by one continuous 
density gradient and showed the higher purity. 
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Figure 12. Silver staining of different Ad preparations after electrophoretic separation on a 
polyacrylamide gel 
5x109 VP of Ad-EGFP, Ad-NIS and Ad-Luc were separated by gel electrophoresis at 120 V for 1.5 
h. Silver staining was performed to investigate for potential impurities. From left to right: Protein 
ladder, Ad-EGFP (from Florian Kreppel), Ad-NIS (from Richard Anderson, ViraQuest Inc.) and 
Ad-Luc (from Per Holm). 
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3.1 Stability of the Ad/PAMAM complexes 
3.1.1 Co-localization of Ad-Alexa488 and PAMAM G5-Cy5 
As stability is a major issue for non-covalent Ad coating, U87MG and HuH7 cells were 
incubated with Ad-Alexa488/PAMAM G5-Cy5 complexes for 2 h at 37 °C to find out if 
Ad and PAMAM G5 remained co-localized in the transduction medium and during the cell 
binding process (Figure 13 and 14). Almost all Ad positive spots exhibited a correlating 
red signal from the Cy5-labeled PAMAM, which is seen as yellow fluorescence in Figure 
13C and F. In addition, numerous PAMAM signals were found especially on HuH7 cells 
(Figure 13E and F), which did not correlate with Ad fluorescence.  
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Figure 13. Co-localization of Alexa488-labeled Ad and Cy5-labeled PAMAM G5 dendrimer  
U87MG and HuH7 cells seeded in chamber slides were transduced with Ad-Alexa488 coated with 
PAMAM G5-Cy5 (MOI 500, 10,000 virus particles/cell). After a 2 h incubation period at 37 °C 
cells were analyzed by LSM. Central sections of U87MG (A-C) or HuH7 (D-F) incubated with Ad-
Alexa488 coated with 100 ng of PAMAM G5-Cy5 are shown. (A, D) Alexa488 signal (green) (B, 
E) PAMAM G5-Cy5 signal (red). (C, F) Overlay; DAPI signal in blue, co-localization Alexa488 
signal and Cy5 signal in yellow. 
 
This was also confirmed using the histo and profile tool within the Zeiss 510 META 
software, where all Alexa488 signals were accompanied by a corresponding more or less 
prominent PAMAM G5-Cy5 signal, but there were also PAMAM G5-Cy5 peaks without 
Alexa488 signal (Figure 14A). This demonstrated that PAMAM was present in excess, 
when using 100 ng of PAMAM G5, where the free dendrimer in solution was subsequently 
internalized by the cells. Co-localization was also observed near the nucleus, indicating 
that the complexes co-translocated together to the nuclear membrane.  
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Figure 14A. Qualitative co-localization analysis of Ad-Alexa488 and PAMAM G5-Cy5 
HuH7 cells seeded in chamber slides were transduced with Ad-Alexa488 coated with PAMAM 
G5-Cy5 (MOI 500, 10,000 virus particles/cell). After a 2 h incubation period at 37 °C, cells were 
fixed with 4% paraformaldehyde, stained with DAPI and analyzed by LSM. The top panel shows a 
central section of cells. The red arrow denotes the line along which the intensity profile in the lower 
panel was analyzed. Lower panel: Intensity profile of Ad-Alexa488 signal (green line), PAMAM 
G5-Cy5 (red line) and DAPI (blue line). 
 
In addition, the co-localization coefficients for the signals were calculated (Figure 14B): in 
both cell lines the overlap coefficient after Manders 105 ranged between 0.7 and 0.8, 
indicating a high degree of correlation. 
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Figure 14B. Quantitative co-localization analysis of Ad-Alexa488 and PAMAM G5-Cy5 
The top left panel shows a central section of the cells (green signal: Ad-Alexa488, red signal: 
PAMAM G5-Cy5) with a red line following the outer cell margins encircling the analyzed area. 
The top right scatter plot shows the co-localization analysis from the encircled area indicating 3 
scatter regions (region 1: Alexa488 signal only; region 2: Cy5 signal only; region 3: co-localization 
of Alexa488 and Cy5 signal); the weighted pixel signal is color-coded with the intensity increasing 
from blue to red. The table summarized the results from the co-localization analysis and indicates 
the overlap coefficient according to Manders.105 
  
3.1.2 Transduction in the presence of FCS 
Furthermore it was investigated how the presence of fetal calf serum (FCS) influences the 
transduction efficiency of Ad/PAMAM complexes in terms of interfering with the 
PAMAM coating. In the first experiment the effect of 2% and 10% FCS on transduction 
was investigated (Figure 15A). When using 10% FCS, the absolute level of luciferase 
expression was reduced both for naked Ad-Luc (2.9-fold) and coated Ad (between 1.8- and 
2.8-fold), but the beneficial effect of PAMAM coating, when looking at the fold increase 
of Ad/PAMAM versus Ad in the respective transduction media, remained stable even in 
the presence of 10% FCS (Figure 15A). To mimic in vivo conditions transductions with 
higher FCS concentrations up to 100% were also performed. When comparing the absolute 
transgene expression levels in Opti-MEM versus their 100% FCS counterparts, a reduction 
of 1.5-fold for Ad-EGFPLuc, 4.2-fold for Ad/PAMAM G5 10 ng and 2.6-fold for 
Ad/PAMAM G5 100 ng respectively could be seen (Figure 15B). The relative fold 
increase in transduction efficiency remained stable up to 25% FCS. In the presence of 
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100% FCS 36% of the relative fold increase could still be maintained for Ad coated with 
10 ng and 58% when Ad was coated with 100 ng PAMAM G5 (Figure 15C).  
 
ng PAMAM G5 
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Figure 15A. Influence of FCS on transduction efficiency 
U87MG cells were transduced with Ad-Luc only or coated with 10 ng, 100 ng or 250 ng of 
PAMAM G5 in Opti-MEM (white bars) or DMEM supplemented with 2% (gray bars) or 10% FCS 
(black bars), and the luciferase level was quantified after 48 h. Mean values (n=5) plus std.dev. are 
shown.  
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Figure 15B-C. Influence of FCS in concentrations up to 100% on transduction efficiency  
U87MG cells were transduced with Ad-EGFPLuc only (striped bars) or coated with 10 ng (grey 
bars) or 100 ng (black bars) of PAMAM G5 in Opti-MEM or DMEM supplemented with 2%-75% 
FCS or pure FCS and the luciferase level was quantified after 48 h (Figure 15B). Additionally, the 
fold increase in transduction efficiency of Ad/PAMAM versus Ad in the respective transduction 
media was calculated (Figure 15C). Mean values (n=3) plus std.dev. are shown. 
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3.3.3 Storage under different temperature conditions 
Coated Ad particles were usually prepared immediately prior to use. For certain 
applications however it would be advantageous to prepare larger amounts of stock, which 
would then require storage. The effect on transduction efficiency after storing coated Ad, 
for 24 h under different conditions, was therefore tested. After coating, particles were 
stored at 4 °C, room temperature or 37 °C for 24 h, and thereafter U87MG or HuH7 cells 
transduced and the transduction efficiency was compared with freshly coated Ad (Figure 
16). Transduction efficiency of coated Ad was only slightly lower or unaffected 
(depending on the amount of PAMAM G5 used for coating), when stored at 4 °C, than of 
freshly coated Ad samples. However, when stored at RT and especially at 37 °C, most of 
the beneficial effect on transduction due to coating was lost. 
 
Ad              Ad/PG5 10ng     Ad/PG5 100ngAd              Ad/PG5 10ng     Ad/PG5 100ng
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Figure 16. Stability of Ad/PAMAM complexes stored at various temperature conditions 
1x104 U87MG (A) and HuH7 (B) cells were transduced in 96-well plates with a MOI of 100 of Ad-
EGFPLuc alone (striped bars) or complexed with 10 ng (grey bars) or 100 ng PAMAM G5 (black 
bars) either freshly prepared or stored for 24 h at 4 °C, RT (20-25 °C) or 37 °C. Luciferase 
expression level was evaluated 48 h after transduction, expressed as relative light units per well 
(RLU/well). Mean values (n=5) plus std.dev. are shown. 
 
3.3.4 Importance of complex formation before application to cells 
Preformed complexes of Ad/PAMAM G5 were compared with a consecutive addition of 
Ad followed by PAMAM G5 into the transduction medium, or alternatively by pre-
incubating the cells with PAMAM G5 for 30 min followed by application of Ad (Figure 17 
A). The latter was performed to rule out a stimulation of macropinocytosis by free 
PAMAM. The best transduction result gained on U87MG by Ad coated with 10 ng 
PAMAM G5 could not be reached by consecutive application or preinbubation with 10 ng 
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PAMAM G5. Whereas consecutive application of Ad and 100 ng PAMAM G5 led to 
results comparable to the preformed complexes, when using an incubation time of 2 h. In 
the next step shorter incubation times of 15, 30 and 60 min were undertaken and the 
preformed complexes were compared with the consecutive addition. While consecutive 
application of Ad and 10 ng PAMAM G5 caused transgene expression levels comparable 
to naked Ad, the values for consecutive addition of Ad and 100 ng PAMAM G5 increased 
with incubation time reaching 68% of the transgene expression levels of preformed 
complexes after an incubation time of 1h.  
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Figure 17. The importance of complex formation before application to cells 
(A) 1x104 U87MG cells were transduced in a 96-well plate for 2 h with a MOI of 100 of uncoated 
Ad-EGPFLuc or preformed Ad/PAMAM G5 complexes versus Ad and PAMAM G5 consecutively 
added or PAMAM G5 applied for 30 min before addition of Ad. (B) Ad or Ad/PAMAM G5 
complexes versus Ad and PAMAM G5 consecutively added were incubated with cells for 15, 30 or 
60 min. 48 h after transduction, luciferase expression level was analyzed and expressed as relative 
light units per well (RLU/well). Mean values (n=5 for A and n=3 for B,C)  plus std.dev. are shown. 
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3.4 Receptor status of different cancer cell lines 
Six different cancer cell lines were tested for their coxsackie- and adenovirus receptor 
(CAR) and integrin αvβ3 levels to predict which cell lines would be easily infected by Ad 
alone and which might benefit from polycation coating. Additionally, cells were stained for 
the epidermal growth factor receptor (EGFR) and the transferrin receptor (TfR) as possible 
receptors for targeting (Figure 18). Receptor levels of additional cell lines can be found in 
the appendix (Figure S1, supplementary information). 
U87MG and HuH7 were used in further studies as representative cell lines with low and 
high CAR levels respectively. In terms of targeting, HepG2 was used as a low EGFR 
expressing cell line and A549 as an EGFR overexpressing cell line. 
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Figure 18. Receptor level estimation of CAR, integrin αvβ3, EGFR and TfR  
Indicated cell lines were stained for CAR, integrin αvβ3, EGFR and TfR and analyzed by flow 
cytometry. Control staining was performed with mouse IgG control antibody. The diagrams on the 
left display the percentage of receptor positive cells for each cell line as well as the mean 
fluorescence intensity (MFI) in the FITC channel above each column. The histograms on the right 
illustrate the shift of Alexa 488 positive cells for every cell line. 
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3.5 Cellular uptake of fluorescently labeled Ad and Ad/polycation complexes  
3.5.1 Cellular uptake of Ad versus Ad/PAMAM G5 complexes 
To study the uptake behavior of uncoated versus coated Ad, Ad-Alexa488 was coated with 
Cy5-labeled PAMAM G5. Two cell lines with different CAR expression levels were 
compared: the human glioblastoma cell line U87MG expressing low CAR levels (3.5% 
CAR positive, MFI 3), and the human hepatocellular carcinoma cell line HuH7, where all 
cells are positive for CAR (100%, MFI 143). U87MG and HuH7 were infected with 
10,000 particles per cell of Ad-Alexa488 alone or complexed with 2.5, 10 or 100 ng of 
PAMAM G5. Cells were incubated with Ad for 2 h at 37 °C, thereafter fixed and cellular 
association and internalization analyzed by flow cytometry and LSM (Figure 19).  
Total cellular association of uncoated Ad as seen by FACS analysis was higher on HuH7, 
when compared to U87MG cells. After virus coating with 10 ng of PAMAM G5, a 6-fold 
increase in MFI was seen on U87MG (Figure 19A). A further increase in PAMAM G5 
concentration to 100 ng did not lead to an additional increase in signal, whereas coating 
with 2.5 ng led to a slightly lower signal shift. On HuH7 cells, the already high cellular 
association of Ad was increased approximately 3-fold using 10−100 ng of PAMAM G5 
(Figure 19B).  
LSM studies were conducted to study intracellular uptake and distribution of Ad and 
Ad/PAMAM G5 within the cell (Figure 19C−H): In the low CAR expressing U87MG cells 
low uptake of uncoated Ad (Figure 19C) was observed, whereas with PAMAM G5 coated 
Ad highly effective internalization occurred, especially when 10 ng of PAMAM G5 were 
used and the Ad/PAMAM G5 particles were small and evenly distributed (Figure 19D). 
Ad/PAMAM G5 complexes were found in close proximity to the nucleus after incubation 
for 2 h, at 37 °C, indicating that the intracellular trafficking was not grossly, negatively 
influenced. HuH7 cells on the other hand exhibited a significant uptake of uncoated Ad 
due to their high level of CAR (Figure 19F), while Ad complexed with PAMAM G5 
tended to form aggregates at the cell membrane. The aggregation process has already been 
observed with low amounts of PAMAM G5, i.e., 10 ng (Figure 19G), which was even 
more pronounced when 100 ng of PAMAM G5 were used (Figure 19H). 
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Figure 19. Influence of PAMAM G5 coating on cellular uptake  
U87MG (low CAR) and HuH7 (high CAR) were transduced with Ad fluorescently labeled with 
amine reactive Alexa Fluor488-5TFP, either alone or coated with PAMAM G5 (MOI 500, 10,000 
VP/cell). After a 2 h incubation period at 37 °C cells were analyzed by either flow cytometry (A, 
B) or LSM (C-H). (A, B) U87MG (A) or HuH7 cells (B) were incubated with Ad-Alexa488 alone 
or coated with 2.5, 10 or 100 ng of PAMAM G5. Cells without virus served as control; 2x104 gated 
events per sample are shown. (C-H) U87MG (C-E) and HuH7 cells (F-H) seeded in chamber slides 
were incubated with Ad-Alexa488 alone (C, F), coated with 10 (D, G) or 100 ng (E, H) of 
PAMAM G5 and fixed with 4% PFA, and the nuclei were counterstained with DAPI and analyzed 
by LSM; for most cells central sections of cells are shown; in panel G some cytoplasmic virus 
signal (green) appears above the nucleus; Alexa488 signal in green, DAPI signal in blue, scale bar 
represents 20 µm. 
 
3.5.2 Cellular uptake of Ad/PAMAM G5 compared to Ad/LPEI complexes  
In order to see if differences between the aggregation and uptake behavior between 
Ad/PAMAM G5 and Ad/LPEI occured, Ad-Alexa 488 was coated with 10 ng of either 
polycation and incubated with cells for 2 h at 37 °C (Figure 20). Coating with LPEI (22 
kDa) led to excessive particle aggregation and reduced uptake resulting in only a few Ad 
Results     44 
particles reaching the nuclear membrane in U87MG (A) and HuH7 cells (B) after 2 h 
compared to PAMAM G5 coated Ad shown in D and in E for U87MG and HuH7 cells 
respectively. 
PG5
LPEI
U87MG HuH7                        Bottom
 
Figure 20. Cellular uptake and aggregation behavior of Ad/LPEI and Ad/PAMAM G5 
U87MG and HuH7 were transduced with LPEI and PAMAM G5 (PG5) coated Ad-Alexa488 (MOI 
500, 10,000 VP/cell). After 2 h at 37 °C cells were fixed and analyzed by LSM. Central sections of 
U87MG (A: Ad/LPEI, D: Ad/PG5) and HuH7 (B: Ad/LPEI 5, E: Ad/PG5) transduced with Ad-
Alexa488 coated with 10 ng LPEI or PAMAM G5 respectively are shown. C (Ad/LPEI) and F 
(Ad/PG5) show the size of the complexes sticking to the bottom of the chamber slide. Alexa488 
signal is illustrated in green, DAPI signal in blue.  
 
3.5.3 Solvent optimization 
While optimizing the coating process, PAMAM G5 and Ad were diluted separately in 
different buffers, including the low ionic buffer HEPES buffered glucose (HBG, pH 7.4), 
PBS and Opti-MEM. The most efficient transduction was obtained with Ad diluted in 
Opti-MEM and PAMAM G5 in HBG, as shown for HuH7 (Figure 21). Hence, all further 
studies were conducted in this buffer system with the exception of zeta potential 
measurements, where PBS was used instead of Opti-MEM for Ad dilution, and TEM, 
where water was used for Ad dilution and PBS for the Ad/PAMAM G5 complex to reduce 
background signal and background staining.  
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Figure 21. The effect of different solvents on transduction efficiency 
1x104 HuH7 hepatoma cells were transduced in 96-well plates with Ad-EGFPLuc (MOI 100) alone 
or complexed with 2.5, 10 and 100 ng PAMAM G5 in the indicated solvents and solvent mixtures. 
The luciferase expression level was evaluated 48 h after transduction and expressed as relative light 
units per well (RLU/well). Mean values (n=3) plus std.dev. are shown. 
 
3.6 Evaluation of the transduction benefit through coating 
3.6.1 Influence of PAMAM G5 and LPEI coating on Ad-Luc mediated transduction 
and metabolic activity of low CAR or high CAR cell lines 
To further investigate the differences between U87MG as low CAR level cell line and 
HuH7 as high CAR level cell line, and to distinguish differences in uptake of Ad/PAMAM 
G5 versus Ad/LPEI, transduction studies based on evaluation of the luciferase transgene 
expression were performed. U87MG and HuH7 cells were transduced with a MOI of 100 
(2x107 VP/well) of uncoated Ad (Ad-Luc) or Ad coated with PAMAM G5 or LPEI ranging 
from 2.5 ng to 1,000 ng per well (Figure 22). In U87MG, uncoated Ad induced only very 
low luciferase expression levels, whereas PAMAM G5 coating induced an increase in 
luciferase expression of up to 36-fold using the optimum amount of 10 ng PAMAM G5 
(Figure 22A). Although HuH7 were highly transducted with uncoated Ad, lower doses of 
PAMAM G5 (2.5 ng) further increased luciferase expression by approximately 30%, 
whereas with higher PAMAM G5 doses the luciferase activity decreased below the level 
achieved with uncoated Ad (Figure 22B). In addition, LPEI (22 kDa), a linear polycation 
and a gold standard in polymer mediated non-viral gene therapy, was evaluated. On 
U87MG cells, LPEI elevated Ad mediated luciferase expression by a maximum of only 
6.5-fold; In HuH7 cells, all LPEI concentrations tested had a negative effect on Ad 
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activity. A MTT assay revealed that cells treated with PAMAM G5 maintained high cell 
viability even when 1,000 ng/well of PAMAM G5 were applied (Figure 22 C,D). In 
contrast, LPEI induced toxicity from 50 ng/well and above and resulted in a cell viability 
of only 3% when incubated with 1,000 ng/well.  
 
Ad 2.
5 10 25 10
0
25
0
10
00 2.
5 10 25 10
0
25
0
10
00
RL
U/
we
ll
A B
C D
ng PAMAM G5           ng LPEI ng PAMAM G5           ng LPEI
 
Figure 22. The influence of PAMAM G5 and LPEI coating on transduction efficiency and 
metabolic activity 
1x104 U87MG glioblastoma (A,C) and HuH7 hepatoma (B,D) cells were transduced in 96-well 
plates with 2x107 Ad-Luc particles/well (MOI 100) either alone (striped bars) or complexed with 
the indicated amounts of PAMAM G5 (grey bars) or LPEI (black bars). Luciferase expression level 
was evaluated 48 h after transduction for U87MG (A) and HuH7 (B) and expressed as relative light 
units per well (RLU/well). MTT assays were also performed for U87MG (C) and HuH7 (D) after 
48h. Untreated cells served as control (white bars) with 100% viability. Mean values (n=3) plus 
std.dev. are shown. 
 
As a further control, 25 kDa branched PEI (BPEI) was used for Ad coating (Figure 23), 
which is similar to 22 kDa LPEI in that it consists of ethylenimine subunits, but in addition 
it is randomly branched and therefore exhibits primary, secondary and tertiary amines 
similar to PAMAM dendrimers. As seen in the previous experiment, PAMAM G5 was 
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greatly superior to LPEI on both cell lines tested. When comparing LPEI to BPEI, LPEI 
worked two times better on U87MG and almost five times better on HuH7 than BPEI. The 
reduction in metabolic activity (Figure 23 C,D) was comparable to that seen for LPEI, 
showing toxicity from 100 ng per well and upwards retaining only 4% cell viability when 
1,000 ng of BPEI per well was applied. 
For further studies, the transduction efficiency using LPEI was compared with the different 
PAMAM dendrimers. 
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Figure 23. The influence of LPEI and BPEI coating on transduction efficiency and metabolic 
activity 
1x104 U87MG glioblastoma (A,C) and HuH7 hepatoma cells (B,D) were transduced in 96-well 
plates with 2x107 Ad-Luc particles/well (MOI 100) either alone (striped bars) or complexed with 
the indicated amounts of LPEI (black bars) or BPEI (light grey bars). Luciferase expression level 
was evaluated 48 h after transduction for U87MG (A) and HuH7 (B) and expressed as relative light 
units per well (RLU/well). MTT assays were also performed for U87MG (C) and HuH7 (D) after 
48h. Untreated cells served as control (white bars) with 100% cell viability. Mean values (n=3) 
plus std.dev. are shown. 
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3.6.2 Comparison of PAMAM G2, G3, G5 and LPEI on 5 human cancer cell lines 
The transduction experiments comparing uncoated versus coated Ad were then extended to 
five human cancer cell lines with a range of CAR expression levels (low CAR level in 
SKOV-3 ovarian carcinoma (MFI 2.6, 0.4% positive) and U87MG glioblastoma (MFI 3, 
3.5% positive), medium CAR level in A549 lung carcinoma (MFI 35.6, 99.2% positive), 
high CAR level in DU145 prostate carcinoma (MFI 122.3, 99.9%) and HuH7 
hepatocellular carcinoma (MFI 143, 100%). The benefit of PAMAM G5 coating in relation 
to the lower generation PAMAMs, namely PAMAM G2 and G3, as well as LPEI was 
examined (Figure 24A-E). For U87MG cells, which express low levels of CAR, the 
highest transduction efficiency was observed with PAMAM G5 followed by G3, G2 and 
LPEI with the best transduction achieved using 10 ng PAMAM G5, 50 ng PAMAM G3 
and 250 ng PAMAM G2, following the trend: the lower the PAMAM generation the more 
coating material is required. In HuH7 an inverse effect was seen, where the best 
transduction efficiency occurred using PAMAM G2 followed by G3, G5 and LPEI. 
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Figure 24 A-E. The coating benefit of PAMAM G2, G3, G5 and LPEI  
1x104 SKOV-3 ovarian carcinoma, U87MG glioblastoma, A549 lung carcinoma, DU145 prostate 
carcinoma and HuH7 hepatoma cells were transduced in 96-well plates with 2x107 Ad-Luc 
particles/well (MOI 100) either alone (striped bars) or complexed with the indicated amounts of 
PAMAM G2 (white bars), PAMAM G3 (light grey bars), PAMAM G5 (dark grey bars) or LPEI 
(black bars). Luciferase expression level was evaluated 48 h after transduction, expressed as 
relative light units per well (RLU/well). Mean values (n=3) plus std.dev. are shown. 
 
MTT assays for all the polycations tested pointed to the absence of toxicity for PAMAM 
G2, G3 and G5 using concentrations up to 1000 ng/well, while LPEI displayed toxicity 
from 50 ng/well and above (Figure 24F-G). 
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Figure 24 F-G. Metabolic activity of U87MG and HuH7 cells after transduction with uncoated Ad 
and PAMAM G2, G3, G5 and LPEI coated Ad 
After 48 h MTT assays were performed for U87MG (F) and HuH7 cells (G). Untreated cells served 
as control (white bars) with 100% cell viability. Mean values (n=3) plus std.dev. are shown. 
 
3.6.3 Correlation of CAR level and transduction improvement by PAMAM G5 
coating 
When taking the highest transduction efficiencies gained with PAMAM G5 (PG5) coating 
in the five cell lines tested, a clear inverse correlation between the CAR expression level 
(Figure 25A) and the benefit gained through transduction with Ad/PAMAM G5 complexes 
compared to uncoated Ad can be observed (Figure 25B). In contrast, no correlation was 
observed between αvβ3 integrin expression levels and improved transduction efficiency due 
to PAMAM coating. SKOV-3 cells, which are virtually CAR negative, showed the greatest 
increase in transduction efficiency (46-fold) using 100 ng of PAMAM G5 for coating, 
followed by U87MG cells which showed a 38-fold increase with 10 ng PAMAM G5. For 
A549 cells a 10-fold increase was found, with an optimum of 50 ng of PAMAM G5, 
whereas DU145 and HuH7 cells, which exhibit high levels of CAR, revealed only a 1.7 
and 1.3-fold increase with a maximum at 50 ng and 5 ng of PAMAM G5 respectively.  
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Figure 25. Correlation between CAR level and increase in transduction efficiency obtained with 
PAMAM G5 
(A) Indicated cell lines were stained for CAR and analyzed by flow cytometry. Control staining 
was performed with mouse IgG control antibody. (B) Cell lines were transduced in 96-well plates 
at MOI 100 with Ad-Luc alone or coated with an optimized amount of PAMAM G5 (SKOV-3, 100 
ng/well; U87MG, 10 ng; A549, 50 ng; DU145, 50 ng; HuH7, 5 ng), and the luciferase activity was 
quantified after 48 h. Relative transduction efficiency was expressed as ratio between luciferase 
activity obtained with PAMAM G5 coated Ad-Luc and uncoated Ad-Luc. Mean values (n=3) plus 
std.dev. are shown. 
 
3.6.4 PAMAM mediated gene delivery: a direct comparison of Ad and plasmid 
As PAMAM dendrimers can be used for both, plasmid 74 and Ad delivery, a side-by-side 
comparison of both systems was conducted using the same polycations and in each case a 
CMV promoter driven EGFPLuc transgene expression cassette. U87MG and HuH7 cells 
were transduced with either an optimal amount of Ad (MOI 100, corresponding to 1×106 
infectious and 1.5×107 total VP) or plasmid at an optimal amount of 400 ng/well 
(corresponding to approximately 5.7×1010 plasmid molecules) (Figure 26). In the low CAR 
cell line U87MG, optimal amounts of plasmid condensed with optimal amounts of the 
most effective PAMAM (400 ng of plasmid condensed with 800 ng of PAMAM G5) still 
only reached luciferase levels about 5-fold below Ad transduced cells; compared to coated 
Ad the level was 102-fold lower. In the CAR positive HuH7 cells, plasmid/PAMAM 
complexes were 55-fold less efficient compared to the naked Ad and 83-fold less efficient 
than the coated Ad. When taking into account that a 57,000-fold excess of DNA molecules 
over infectious Ad particles was used, Ad coated with PAMAM G5 dendrimer led to 
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5.8×106 and 4.7×106-fold increases in transgene expression level versus DNA/PAMAM 
polyplexes in U87MG and HuH7 cells respectively. 
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Figure 26. Comparision of DNA/PAMAM polyplexes with PAMAM coated Ad 
1x104 U87MG (A) or HuH7 cells (B) were transfected in 96-well plates with either DNA/PAMAM 
polyplexes (400 ng DNA, optimum w/w of 4/1 or 2/1 PAMAM G2/G3/G5 to DNA) or Ad-
EGFPLuc coated with the indicated amounts of PAMAM G2 (light grey bars), PAMAM G3 
(medium grey bars) or PAMAM G5 (dark grey bars). Luciferase expression level was evaluated 48 
h after transduction, expressed as relative light units per well (RLU/well). Mean values (n=3) plus 
std.dev. are shown. 
 
3.7 Protection ability of PAMAM dendrimer coating from inhibition by 
neutralizing antibodies 
In order to study the ability of the PAMAM G5 dendrimer to protect the Ad from 
neutralizing antibodies, uncoated Ad-EGFP or preformed Ad/PAMAM G5 complexes with 
25 or 100 ng PAMAM G5 were incubated for 30 min with increasing concentrations of 
human IgG (Privigen®, obtained from pooled plasma taken from 60,000 donors, stock 100 
mg/mL) before transducing A549 cells. FACS analysis for EGFP 48 h after transduction 
revealed that uncoated Ad was rapidly inactivated by IgG exposure reaching a baseline 
level of 0.5% positive cells, when incubated with 0.8 mg/mL of IgG (1:120 dilution), while 
PAMAM coated Ad was still able to transduce 65% of the cells, on average, with the same 
IgG concentration. At IgG concentrations reaching 3.3 mg/mL (1:30 dilution), 100 ng of 
PAMAM G5 still helped to protect the Ad from inhibition by neutralizing antibodies, 
therefore enabling infection of 47% of the cells on average (Figure 27 and S3, 
supplementary information).    
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Figure 27. The protective effect of PAMAM G5 coating on transduction in the presence of anti-
adenovirus neutralizing antibodies 
5x104 A549 cells seeded in 24-well plates were transduced with Ad-EGFP alone (triangles) or 
coated with 25 ng (squares) or 100 ng (diamonds) of PAMAM G5 at a MOI of 100. A range of IgG 
concentrations (Privigen®) were incubated with uncoated Ad or Ad/PAMAM G5 complexes for 30 
min before application to A549 cells. After 48 h, EGFP expression was analyzed by flow 
cytometry. Representative data from 3 independent experiments are shown. Mean values (n=2) ± 
std.dev. are illustrated. 
 
To rule out the possibility, that free PAMAM G5 inactivates the anti-Ad IgG contained in 
Privigen® an indirect ELISA was performed to check for PAMAM G5-Privigen® 
interaction. Therefore immobilized Ad was incubated with anti-Ad IgG dilutions (1:250 to 
1:512,000), which were either preincubated for 30 min at RT with 100 ng PAMAM G5 in 
HBG or HBG buffer only. Both conditions tested enabled approximately the same amount 
of HRP-labeled goat anti-human-IgG antibody to bind to the immobilized Ad, leading to 
almost identical absorbance curves of the o-phenylenediamine dihydrochloride (OPD) 
containing substrate solution. 
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Figure 28. Testing the interaction of anti-Ad IgG with PAMAM G5 using an indirect ELISA 
6x108 VP/well were added to a Nunc Maxisorb 96-well plate and allowed to adhere o.n. at 4°C, 
while two rows were coated with coating buffer only for control samples (squares). Privigen® 
dilutions were either incubated with 100 ng PAMAM G5 for 30 min at RT (black triangles) or 
incubated with HBG buffer (grey triangles) only, before addition to the immobilized Ad. A HRP-
labeled secondary antibody was used, followed by an OPD (o-phenylenediamine 
dihydrochloride) substrate solution. Absorbance was measured at 485 nm with background 
correction at 635 nm. Mean values (n=3 for samples, n=2 for control) ± std.dev. are shown. 
 
Beside PAMAM G5, PAMAM G3 and PAMAM G2 were also tested for their ability to 
protect the Ad from neutralizing antibodies. PAMAM G5 gave superior protection 
compared to PAMAM G3 followed by PAMAM G2 especially when high IgG 
concentrations were used.  
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Figure 29. Comparison of the protective ability of PAMAM G2, G3 and G5 coating against 
neutralizing antibodies  
5x104 A549 cells seeded in 24-well plates were transduced with Ad-EGFP alone (triangles) or 
coated with 500 ng PAMAM G2 (light grey squares), 100 ng PAMAM G3 (dark grey squares) or 
100 ng PAMAM G5 (black sqares) at a MOI of 100. A range of IgG concentrations (Privigen®) 
were incubated with uncoated Ad or Ad/PAMAM complexes for 30 min before application to 
A549 cells. After 48 h, EGFP expression was analyzed by flow cytometry. Mean values (n=2) ± 
std.dev. are shown. 
 
3.8 Factor X binding assay 
Besides inactivation by neutralizing antibodies, which becomes important when thinking 
about a clinical application, two main cellular interactions are responsible for loss of vector 
as well as appearance of toxicity after intravenous injection. The majority of adenovirus 
vectors injected intravenously are scavenged by Kupffer cells, macrophages which are 
located in the liver.39 Additionally the adenovirus type 5 is known to bind coagulation 
factor X (FX) with its hexon protein, leading to hepatocyte transduction.43-45 To examine 
the potential of PAMAM G5 to abolish FX-hexon interaction and therefore hepatocyte 
transduction a factor X binding assay was performed (Figure 30). Ad-EGFP coated with 
increasing amounts of PAMAM G5 was incubated with SKOV-3 cells with or without 
addition of physiological concentrations of factor X (8 µg/mL) into the transduction media. 
Two controls were investigated in parallel, one where FX binding was genetically ablated 
through exchange of the hyper variable region 5 (HVR5) by the peptide CKS 17 binding 
TGF beta, and a second one where FX binding was chemically ablated due to covalent 
coupling of a 750 Da MeO-PEG-Mal to HVR5 of an Ad containing a genetically 
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incorporated cysteine. Like the Ad-EGFP, both were coated with increasing amounts of 
PAMAM G5 and 72 h after transduction, cells were analyzed for EGFP expression. 
Independently of the PAMAM G5 concentration used, both control vectors failed to show 
an increase in transduction efficiency in the presence of FX, proving the FX binding 
ablation. In contrast Ad-EGFP, when coated with amounts as small as 10 ng of PAMAM 
G5 caused even higher EGFP levels in the presence of FX than uncoated Ad. This led to 
the hypothesis that both, PAMAM G5 and FX, contributed to uptake via heparan sulfate 
proteoglycans (HSPGs). Only when the amounts of PAMAM particles exceeded the 
amounts of FX molecules, could a reduction in transgene expression in the presence of FX 
be seen. 
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Figure 30. Factor X binding assay 
2x104 SKOV-3 cells seeded into 96-well plates were transduced with 1000 VP/cell Ad-EGFP or the 
genetically FX-binding ablated Ad-CKS-17 and the chemically FX-binding ablated Ad-PEG-750 Da 
as controls in the presence (black bars) or absence (light grey bars) of FX at a concentration of 8 
µg/mL. After 72 h, EGFP expression was analyzed by flow cytometry. Mean values (n=2) ± 
std.dev. are shown. 
 
3.9 Targeting of Ad to the epidermal growth factor receptor (EGFR) 
Having a system at hand that increases uptake in CAR positive, and to a much stronger 
extent in CAR negative cell lines, the aim was to increase the specificity of uptake and 
therefore transgene expression for tumor cells expressing distinct receptors on their 
surface. EGFR, upregulated in several cancer types like head and neck, ovarian and breast 
cancer and a common target of antitumor therapies,85,90 was chosen as the target receptor. 
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As EGF, the natural ligand for the EGFR, has a mitogenic potential, we used GE11, a 
peptide ligand known to bind the EGFR without receptor activation.92 The peptide was 
coupled to a PAMAM G2 dendrimer via a 2 kDa PEG spacer and a PAMAM G2-PEG-Cys 
conjugate with a distal cysteine was used as control for Ad coating (Figure 31). In HepG2 
cells, which express only low levels of EGFR (MFI 6.6, 29.3% EGFR positive), no 
significant difference in transgene expression was observed between PAMAM-PEG-Cys 
and PAMAM-PEG-GE11 coated Ad-EGFP, either by flow cytometry (Figure 31A) or by 
laser scanning microscopy (Figure 31 C,D). In contrast, the GE11 conjugate was able to 
induce a significantly higher increase (up to 2.3-fold) in EGFP expression in the highly 
EGFR positive lung carcinoma cell line A549 (MFI 213.9, 100% EGFR positive) when 
compared to PAMAM-PEG-Cys coating (Figure 31 B: flow cytometry, E and F: laser 
scanning microscopy), especially with lower amounts of conjugate.  
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Figure 31. Targeting of Ad to the EGFR using PAMAM G2-PEG-GE11 for coating 
HepG2 (A, C, D) or A549 cells (B, E, F) seeded in 24-well plates (A, B) or chamber slides (C-F) 
were transduced at a MOI of 100 with Ad-EGFP alone or coated with the indicated amounts of 
PAMAM G2-PEG-GE11 or PAMAM G2-PEG-Cys. EGFP expression was analyzed 48 h after 
transduction. (A, B) MFI of transduced cells (striped bars: Ad-EGFP, light gray bars: PAMAM G2-
PEG-Cys coated Ad, dark gray bars: PAMAM G2-PEG-GE11 coated Ad. (C-F) Laser scanning 
microscopy of cells transduced with Ad-EGFP coated with 25 ng of PAMAM G2-PEG-Cys (C, E) 
or PAMAM G2-PEG-GE11 (D, F). * p<0.05, ** p<0.01, PAMAM G2-PEG-Cys versus PAMAM 
G2-PEG-GE11, t test unpaired. 
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To further specify the GE11 targeting effect, the EGFR was downregulated before 
application of the PAMAM-PEG-GE11 versus its control construct. To find the most 
effective condition for EGFR downregulation, cells were pre-incubated for 45 min at 37 °C 
with Cetuximab, an antibody known to cause internalization of the EGFR after binding,85 
or with murine EGF (mEGF), as a substitute for the natural ligand (Figure 32). Thereafter 
FACS analysis to determine the EGFR level was undertaken, where untreated cells stained 
for EGFR served as control. From the concentrations tested, 0.1 µg/well worked best for 
Cetuximab leading to a 1.4-fold reduction in the mean fluorescence intensity (MFI) of the 
Alexa 488 signal, whereas mEGF in a concentration of 10 µg/well induced a 4.2-fold 
reduction. Therefore the use of 10 µg/well mEGF was continued for receptor 
downregulation before transduction. 
 A
 
Figure 32. Downregulation of the EGFR using Cetuximab and mEGF 
1x104 A549 cells were seeded in a 96-well plate and incubated with increasing amounts of 
Cetuximab or mEGF (0.1, 1 and 10 µg/well) for 45 min at 37 °C. Thereafter cells were stained with 
mouse anti-EGFR followed by Alexa 488 labeled secondary antibody and analyzed by flow 
cytometry. Untreated cells stained for EGFR served as control. Mean values of Alexa488 signal 
(MFI) plus std.dev. are shown (n=2). 
 
According to the transduction with Ad-EGFP, transduction using Ad-EGFPLuc and 
PAMAM G2-PEG-GE11 versus its control construct PAMAM G2-PEG-Cys was 
performed (Figure 33A). Pre-incubation with mEGF reduced transgene expression of the 
PAMAM G2-PEG-GE11 coated Ad-EGFPLuc significantly, whereas PAMAM G2-PEG-
Cys coated Ad-EGFPLuc was unaffected, further proving the specificity of the system 
(Figure 33B). 
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Figure 33. Showing specificity of the PAMAM PEG-GE11 after downregulation of the EGFR 
(A) 1x104 A549 cells were transduced with Ad-EGFPLuc (MOI 100) coated with PAMAM G2-
PEG-GE11 (dark grey) or the control construct PAMAM G2-PEG-Cys (light grey). (B) For the 
best targeting condition found (10 ng), a pre-incubation with 10 µg/well mEGF is shown. Light and 
dark grey, respectively, without mEGF pre-incubation, striped bars with mEGF pre-incubation. 
Mean values (n=3) + std.dev. are shown, unpaired t-test, * p< 0.05. Luciferase expression level was 
evaluated 48 h after transduction, expressed as relative light units per well (RLU/well).  
 
3.10 In vivo experiments on biodistribution 
Once the hybrid system of Ad non-covalently coated by PAMAM dendrimers was 
characterized and optimized in vitro, the protective ability and therefore the inability to 
target off-target organs like liver and spleen was tested. 
For the initial in vivo experiments, the focus was put on biodistribution of the naked versus 
the PAMAM G5 coated Ad without taking receptor targeting into consideration. Female 
Balb/c mice with an age of 6-8 weeks where injected intravenously with 3x1010 VP of Ad-
EGFP either uncoated or coated with 250 or 1500 ng PAMAM G5. 72 h later mice were 
sacrificed by an overdose of isoflurane and organs were harvested. Biodistribution was 
analyzed by virus copies per cell using qPCR as well as on the transgene expression level 
by performing laser scanning microscopy on cryosections and fluorometric measurements 
of liver homogenates.  
 
3.10.1 Fluorometry of liver homogenates 
For analysis of transgene expression level, 0.5 g of each mouse liver was homogenized in a 
conical tissue grinder using 1 ml RIPA buffer (50 mM Tris, 1% NP-40, 0.25% sodium 
desoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, pH 7.4) and EGFP 
fluorescence of the supernatant was measured at 488 nm excitation and 512 nm emission 
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wavelength with a LS50B spectrometer. In the first experiment mice were divided into 
three groups (n=3), namely Ad only, Ad coated with 250 ng PAMAM G5 and Ad coated 
with 250 ng of a PAMAM G5 construct carrying a 2 kDa PEG chain and a terminal 
cysteine (PAMAM G5-PEG-Cys). With 250 ng PAMAM G5 there was already a trend 
towards increasing fluorescence visible, ranging from Ad over Ad/PAMAM G5-PEG-Cys 
to Ad/PAMAM G5 (Figure S4, supplementary information). In the second experiment the 
amount of PAMAM G5 was increased to 1500 ng and two groups were investigated, Ad 
versus Ad/PAMAM G5 1500 ng (Figure 34). When 1500 ng PAMAM G5 were used for 
coating a significant 3.2-fold increase in fluorescence intensity for the coated Ad could be 
seen compared to the uncoated Ad (n=4), therefore exhibiting a targeting rather than a 
detargeting from the liver. 
 
*
 
Figure 34. Fluorometric measurement of liver homogenates after Ad versus Ad/PAMAM G5 
application 
Mice were injected intravenously with either 3x1010 VP of Ad-EGFP (light grey bar) or Ad-EGFP 
coated with 1500 ng PAMAM G5 (PG5, dark grey bar) in a PBS/HBG 1:1 mixture. After 72 h 
mice were sacrificed and prepared liver homogenates were used for EGFP fluorescence 
measurement at 488 nm excitation and 512 nm emission wavelength. Mean values (n=4) ± std.dev. 
are shown. Additionally liver fluorescence of an untreated control animal is shown.  Unpaired t-
test, two-tailed, one sided * p< 0.05. 
 
3.10.2 Cryosections 
To get an overview of the EGFP expression on a single cell level, 6 µm sections of PFA fixed 
and Tissue-Tek embedded spleen and liver samples were cut using a Leica CM3050S-
cryostat. Samples were analyzed by confocal laser scanning microscopy (Figure 35). Liver 
sections of Ad coated with 250 ng PAMAM G5 showed again a trend towards higher 
fluorescence and can be found in the appendix (Figure S4, supplementary information). When 
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1500 ng of PAMAM G5 was used for Ad coating, liver sections showed a pronounced 
increase in the number of positive cells and in the intensity of fluorescence, hence matching 
the results obtained by liver fluorometry. For spleen sections a difference could not be seen by 
eye for either PAMAM concentration used (Figure 35A).  
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Figure 35. Cryosections of spleen and liver after Ad-EGFP versus Ad-EGFP/PAMAM G5 
application 
6 µm sections of spleen (A) and liver (B) were cut using a Leica cryostat and analyzed with a 
confocal laser scanning microscope. Top row in each panel shows Ad only, bottom row shows Ad 
coated with 1500 ng PAMAM G5 (n=4).  
 
3.10.3 Quantitative real time PCR (qPCR) 
Additionally the distribution of virus particles in spleen and liver tissue was analyzed by 
qPCR (Figure 36). QPCR was carried out by amplification of the Ad E4 gene using 2x 
Brilliant II SYBR® Green qPCR Master Mix for quantification. CT values obtained for E4 
were normalized to β-actin levels. Copy numbers of Ad/cell were calculated using an E4 
standard equation, gained from an E4 standard run in parallel on every plate. The copy 
numbers of Ad/cell showed a significant increase for the Ad/PAMAM G5 1500 ng liver 
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samples, while in the spleen samples there was an indication of an increase.  
In summary an increase in transgene level, seen by liver fluorometry and cryosections, as 
well as on the number of virus particles per cell, analyzed by qPCR, was found after 
PAMAM G5 coating. This effect was more prominent for 1500 ng (equals 1044 molecules/ 
Ad) than for 250 ng PAMAM G5 (equals 174 molecules/Ad) used for coating. 
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Figure 36. QPCR of Ad E4 gene in spleen and liver tissue after Ad or Ad/PAMAM G5 application 
A qPCR for the E4 gene of spleen (A) and liver (B) samples after application of Ad (light grey 
bars) or Ad/PAMAM G5 1500 ng (dark grey bars) application was performed. Samples were run in 
duplicate and the gained averaged E4 CT values were normalized against β-actin. Copy numbers of 
Ad/cell were calculated using an E4 standard run in parallel. Unpaired t-test, two-tailed, * p< 0.05. 
 
3.11 Biodistribution study comparing two different mouse strains 
The initial animal studies on biodistribution were performed with the immunocompetent 
BALB/c mice, an albino laboratory-bred strain of the house mouse, which belongs to the 
most widely used inbred strains. As for tumor implantation an immunodeficient mouse 
strain was needed, CD 1 nu/nu mice were tested side by side for differences in 
biodistribution and transgene expression after intravenous Ad (Ad-EGFP) and 
Ad/PAMAM G5 application. CD 1 nu/nu mice lack a thymus and are therefore unable to 
produce T-cells, making them ideal models for xenograft research. 2.2x1010 VP of Ad or 
Ad coated with 300 ng PAMAM G5 (equals 285 PAMAM molecules/Ad) were injected 
intravenously in 200 µL of an Opti-MEM/HBG 1:1 mixture. After 72 h mice were 
sacrificed, and organs harvested for liver fluorometry, laser scanning microscopy of 
cryosections and qPCR, (Figure 37) as described earlier. After application of Ad/PAMAM 
G5 compared to Ad only both mouse strains exhibit a clear increase in virus particles per 
cell (VP/cell) in all organs tested, which was significant for lung of Balb/c and kidney and 
liver of CD 1 nu/nu. Fluorometry results for Balb/c showed a significant 4.1-fold increase, 
while results for CD 1 nu/nu showed a trend towards increased fluorometry, but were not 
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significant due to an outlier in the Ad only group. Cryosections did again confirm the 
fluorometry results gained. In summary both mice strains indicated an increase of VP/cell 
as well as in transgene expression levels after PAMAM coating of Ad, with the difference 
of CD 1 nu/nu displaying an overall higher EGFP expression in the liver, while EGFP 
expression in the spleen is clearly stronger in the immunocompetent Balb/c. A 
representative cryosection of lung, kidney (non-target organs) and spleen and liver (natural 
target organs) is presented in figure 37. An overview of all cryosections can be found in 
the appendix (Figure S5, supplementary information). 
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Figure 37. Biodistribution study of i.v. injected Ad versus Ad/PG5 in Balb/c versus CD1 nu/nu 
Liver fluorometry, cryosections and qPCR results for Balb/c (A, C, E) and CD 1 nu/nu (B, D, F). 
n= 5, unpaired t-test, two-tailed * p< 0.05. 
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3.12 Establishment of a SKOV-3 intraperitoneal cancer mouse model 
In order to reach a well vascularized tumor after intravenous application of Ad, it is 
important to mediate detargeting from the liver and prevent loss of vector, as well as 
increasing the circulation half life. As the non-covalent coating approach of Ad-EGFP 
using PAMAM dendrimers seemed unpromising in mediating this detargeting effect, the 
idea was to use an alternative application route. Therefore, SKOV-3 LucEGFP ovarian 
carcinoma cells were implanted intraperitoneally (i.p.) and the Ad should be applied via 
the same application route, hoping to bypass FX mediated hepatocyte transduction. SKOV-
3 cells are known to be hardly transducable by Ad alone,106 therefore giving the possibility 
to evidence the PAMAM coating benefit. Additionally up to 60% of ovarian cancers over-
express the epidermal growth factor receptor (EGFR),107 as proved for SKOV-3 cells used 
in this study, creating the opportunity to target the EGFR using the PAMAM-PEG-GE11 
constructs.  
 
3.12.1 In vitro characterization of SKOV-3 LucEGFP cells 
3.12.1.1 Quantification of the luciferase and EGFP expression level 
The SKOV-3 LucEGFP cells, obtained from the lab of Nori Kasahara, were first tested for 
their luciferase as well as EGFP expression level (Figure 38). To quantify the luciferase 
expression 2,000, 5,000 and 10,000 cells were seeded in a 96-well plate and, after 24 h, 
cells were lysed and a luciferase assay was performed. For 2,000 cells seeded 5.1x107 RLU 
were found, proving a high luciferase expression level. Additionally the EGFP level was 
quantified by FACS analysis revealing a mean fluorescence intensity (MFI) of 113 and 
94.1% of EGFP positive cells. 
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Figure 38. Quantification of the luciferase and EGFP expression level 
(A) 2x103, 5x103 and 1x104 SKOV-3 LucEGFP cells were seeded in a 96-well plate. After 24 h, 
cells were lysed and the luciferase activity was quantified. 2 ng of recombinant luciferase 
correspond to 107 relative light units (RLU). Mean values (n = 6) plus std.dev. are shown.  
(B) 2x104 gated cells were analyzed by FACS for EGFP expression using A549 cells as control for 
laser adjustment (histogram: MFI; density plot: % positive cells). 
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3.12.1.2 Estimation of the CAR, integrin, TfR and EGFR levels 
SKOV-3 LucEGFP cells were analyzed for their coxsackie- and adenovirus receptor (CAR), 
integrin αvβ3 as well as transferrin receptor (TfR) and epidermal growth factor receptor 
(EGFR) levels using an Alexa 647 labeled secondary antibody (Figure 39). The number of 
positive cells was obtained by diagonal gating using the APC channel versus the APC Cy7 
channel. A low CAR level (MFI 11.7, 28.4% positive) and overexpression of the EGFR (MFI 
1346.8, 100% positive) were confirmed. 
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Figure 39. Receptor level estimation of CAR, integrin αvβ3, TfR and EGFR 
SKOV-3 LucEGFP cells were stained for CAR, integrin αvβ3, TfR and EGFR using a 647 labeled 
secondary antibody and analyzed by flow cytometry. Control staining was performed with a mouse 
IgG control antibody. The diagram on the left displays the percentage of receptor positive cells for 
each receptor tested as well as the mean fluorescence intensity (MFI) in the APC channel above 
each column. The histogram on the right illustrates the shift in the APC channel of receptor 
positive cells. 
 
To assess the EGFR level of SKOV-3 LucEGFP cells compared with HepG2 (low EGFR 
expression) and A549 (high EGFR expression) the three cell lines were stained for EGFR 
using the 647 labeled secondary antibody (Figure 40). For the SKOV-3 LucEGFP a 2.4 
fold higher MFI was measured compared to A549, making them the cells with the highest 
EGF receptor density of the cells analyzed. 
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Figure 40. Comparison of the EGFR level of HepG2, A549 and SKOV-3 LucEGFP cells 
HepG2, A549 and SKOV-3 LucEGFP were stained for EGFR using a 647 labeled secondary 
antibody and analyzed by flow cytometry. Control staining was performed with a mouse IgG 
control antibody. The diagram on the left displays the percentage of receptor positive cells for each 
cell line as well as the mean fluorescence intensity (MFI) in the APC channel above each column. 
The histogram on the right illustrates the shift of Alexa 647 positive cells for every cell line. 
 
3.12.2 Establishment of a dual color system 
When considering an in vivo application, SKOV-3 LucEGFP provided the opportunity to 
correlate the luciferase signal with tumor growth, and enabling the best time point for 
vector application to be found. Additionally due to EGFP expression, tumor tissue can be 
distinguished from mouse tissue using fluorescence microscopy with an excitation 
wavelength of 488 nm and a 505/30 band pass filter. To show the possibility that the Ad 
infected cells are in fact SKOV-3 LucEGFP cells, an Ad expressing a fluorescent transgene 
with a wavelength distinguishable from that of EGFP was needed. Therefore a mCherry 
transgene containing construct under an EF1α-promotor was cloned. mCherry has an 
excitation maximum at 587 nm and an emission maximum of 610 nm. Excitation 
wavelength and emission filter combinations for both fluorophores were optimized for 
laser scanning microscopy (LSM) as well as FACS analysis. LSM was performed later 
using a 488 nm argon laser for extinction and a 505-530 nm band pass filter for detection 
of EGFP. For mCherry a 543 nm helium-neon laser was used for excitation and a 560 nm 
long pass filter for detection. For FACS analysis an excitation wavelength of 488 nm was 
used for EGFP with a 530/40 nm band pass filter for detection. The optimum excitation for 
mCherry was gained with the 488 nm laser, while for detection a PE-Cy5 filter (680/30 nm) 
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was used. In the FACS optimization process diagonal gating of the FITC versus the PE, 
PE-Texas Red, PE-Cy5,  PE-Cy7 and APC channel was performed, and are presented in 
figure S6 in the appendix. A scheme showing the excitation and emission spectra of EGFP 
and mCherry, as well as the laser excitation wavelengths and emission filters is illustrated 
below (Figure 41). 
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Figure 41. Excitation and emission spectra of EGFP and mCherry 
The excitation and emission spectrum for EGFP is illustrated in blue and green respectively. For 
mCherry the excitation spectrum is shown in orange and the emission spectrum in red. Peak 
wavelengths are depicted above the spectra and laser excitation wavelengths and emission filters 
are illustrated with an arrow or colored bar below the spectra. EGFP and mCherry spectra were 
created using http://www.tsienlab.ucsd.edu/Documents.htm and adapted from (Picard, 
Experimental Cell Research, 2006).108 
 
3.12.2.1 Cloning of the Ad-mCherry construct 
As starting vectors the pCpG-hCMV EF1α-TNF and the pCpG-hCMV SCEP-mCherry, 
cloned by Rudolf Haase, were used. Both were digested with HindIII and SpeI and the 
EF1α-promotor inserted into the mCherry containing backbone. This resulted in the 3667 
bp construct pCpG-hCMV EF1α-mCherry carrying a zeocin resistance. The insertion of 
the EF1α promotor was verified by digestion with the restriction enzymes SmlI and NheI. 
In the final step the pCpG-hCMV EF1α-mCherry was digested with PacI and inserted into 
a pGs66 backbone also cut with PacI (Figure 42). The 38727 bp construct pGs66-hCMV 
EF1α-mCherry was linearized with SwaI and N52E6 cells were transfected with the help 
of LPEI for virus production. 
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Figure 42. Cloning scheme for Ad-mCherry 
Step 1: The EF1α promoter was cut out of the pCpG-hCMV EF1α-TNF construct by HindIII and 
SpeI and inserted into the pCpG-hCMV-mCherry backbone. Step 2: The hCMV-EF1α-mCherry 
expression cassette was cut out by PacI and inserted into the PacI site of the pGs66 backbone. 
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3.12.2.2 Comparison of PAMAM G2, G3 and G5 for coating of Ad-mCherry 
SKOV-3 LucEGFP cells were transduced with Ad-mCherry only or coated with PAMAM 
G2, G3 or G5 at an optimized amount and analyzed by FACS and LSM to prove that both 
fluorophores could be detected separately (Figure 43 A-C).  
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Figure 43. Evaluation of the beneficial effect of PAMAM G2, G3 and G5 coating by FACS and 
LSM using Ad-mCherry at a MOI of 125 
2.5x104 SKOV-3 LucEGFP cells seeded in 24-well plates (FACS) or 8-well chamber slides (LSM) 
were transduced at a MOI of 125 with Ad-mCherry alone or coated with the indicated amount of 
PAMAM G2, G3 and G5. After incubation for 48 h, cells were either subjected to FACS analysis 
or LSM imaging. (A-B) FACS analysis of SKOV-3 LucEGFP transduced with Ad-mCherry only 
(stripped bars) or coated with PAMAM G2 (light grey bars), PAMAM G3 (medium grey bars) or 
PAMAM G5 (dark grey bars). (A) Illustrates the mean fluorescence intensity (MFI) gained in the 
PE-Cy5 channel, while (B) shows the percentage of transduced cells. Mean values (n=3) plus 
std.dev. are shown. (C) Laser scanning microscopy (LSM) images of control cells versus Ad-
mCherry only and Ad-mCherry coated with PAMAM G2, G3 and G5. Upper panel shows the 
EGFP signal from SKOV-3 LucEGFP cells as well as the mCherry signal. The lower panel depicts 
the mCherry signal only. 
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As seen before, with other low CAR level cell lines using Ad-Luc, the most beneficial 
effect on transduction was gained by PAMAM G5 coating, followed by G3 and G2. With 
PAMAM G5 used for coating and Ad-mCherry at a MOI of 125, 91.5% of mCherry 
positive cells were observed compared to 12.9% with uncoated Ad. The increase in the 
number of positive cells as well as an increase in the intensity of fluorescence from 
PAMAM G2 to G5 was confirmed by laser scanning microscopy (LSM) shown in figure 
43 C, with a 63x magnification. 10x magnification images of all PAMAMs can be found in 
figure S7 in the appendix. 
When using Ad-mCherry at a MOI of 500 for transduction (Figure 44), the percentage of 
mCherry expressing cells was above 97% for all the PAMAM generations tested and the 
increase in MFI reached a maximum of 28-fold higher for PAMAM G5 coating in relation 
to uncoated Ad-mCherry. Images at 63x magnification and 10x magnification, to give an 
overview of effectively transduced cells, are exemplified in figure 44C for PAMAM G5 
coating. 
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Figure 44. Evaluation of the beneficial effect of PAMAM G2, G3 and G5 coating by FACS and 
LSM using Ad-mCherry at a MOI of 500 
Experimental setup as shown in figure 43. (A-B) FACS analysis illustrating the MFI (A) versus % 
of positive cells (B). (C) LSM images of control, Ad-mCherry only and PAMAM G5 coated Ad-
mCherry in a 63x magnification (top panel) and a 10x magnification (lower panel). 
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3.12.2.3 Comparing PAMAM-PEG-GE11 generation 2, 3 and 5 
Ad coated with PAMAM G2-PEG-GE11, which had been proven to effectively target the 
EGFR, overexpressed on A549 cells, was directly compared to complexes formed with 
PAMAM G3-PEG-GE11 and PAMAM G5-PEG GE11. As individual control, a PAMAM-
PEG-Cys of the particular generation was used for coating. For PAMAM G2-PEG-GE11 a 
significant increase in the intensity of fluorescence was measured by FACS analysis 
compared to the PAMAM G2-PEG-Cys construct. For PAMAM G3-PEG-GE11 a 
tendency towards higher fluorescence could still be seen, and in the case of PAMAM G5-
PEG-GE11 the cysteine construct gained higher fluorescence levels than the targeting 
construct. As with the lower generation PAMAMs a higher amount of dendrimer was 
needed for an optimal coating benefit, a higher GE11 density was present in the 
complexes. In the case of PAMAM G2-PEG-GE11 compared to G3 there was a 6-fold 
difference in GE11 concentration and an even bigger difference, 56-fold, between 
generation 2 and 5. 
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Figure 45. Comparing the different PAMAM-PEG-GE11 constructs for their targeting properties 
(A) 2.5x104 SKOV-3 LucEGFP cells were seeded in 24-well plates and transduced with Ad (MOI 
125) only or coated with PAMAM-PEG-GE11 or the respective control construct PAMAM-PEG-
Cys of each generation for 2 h at 37 °C. 2x104 gated cells were analyzed by FACS using the FITC 
versus the PE-Cy5 channel for diagonal gating. MFI of transduced cells (striped bar: Ad-mCherry, 
light gray bars: PAMAM-PEG-Cys coated Ad, dark gray bars: PAMAM-PEG-GE11 coated Ad of 
the indicated PAMAM generations). Mean values (n=3) plus std.dev. are shown.* p < 0.05, t test 
unpaired. (B) Scheme of the coupling ratio of PAMAM to GE11 for every generation, including 
the fold increase in GE11 present, with respect of the amounts of PAMAM used for coating. 
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3.12.3 In vivo characterization of SKOV-3 LucEGFP cells 
3.12.3.1 Luciferase imaging   
After in vitro characterization, including evaluation of the luciferase and EGFP gene 
expression level, the receptor expression levels as well as the transduction benefit through 
PAMAM coating of Ad, SKOV-3 LucEGFP cells were tested for their in vivo 
characteristics. Therefore 5x106 SKOV-3 LucEGFP cells were injected intraperitoneally 
(i.p.) into Rj:NMRI-nu (nu/nu) mice on day 0 and luciferase imaging was performed twice 
per week using a CCD camera (IVIS Lumina™) and the Living Image software 3.2 
(Caliper Life Sciences, Hopkinton, USA). For imaging mice were anesthetized with 3% 
isoflurane in oxygen, 100 µL luciferin solution (c=60 mg/mL) was injected i.p. and light 
efflux recorded after 10 min. Mice showed a lag phase in tumor growth of two to four 
weeks, where luciferase signals barely remained constantly, after which the signal 
increased exponentially (Figure 46). At the time point mice were killed tumor nodules 
were below 5 mm.  
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Figure 46. Luciferase imaging of SKOV-3 LucEGFP cells implanted i.p. in NMRI mice 
5x106 SKOV-3 LucEGFP cells were injected intraperitoneally in NMRI nude mice and luciferase 
imaging performed twice per week. Mice were sacrificed between day 21 and day 45 when the 
exponential growth phase started. Organs were harvested, fixed with PFA and embedded in 
paraffin.  
 
After removal of the organs luciferase imaging was performed to highlight the SKOV-3 
LucEGFP tumors (Figure 47). Tumor nodules were typically found in the lesser curvature 
of the stomach, between the liver lobes, in the adherent tissue of the spleen and in the small 
and large intestines. 
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Figure 47. Luciferase imaging of organs carrying tumor nodules 
After mouse 3 was sacrificed at day 45, 10 min after luciferin application, organs were removed 
and a luciferase imaging performed. Numbers refer to the organs listed in the picture on the left. 
The white arrows on the right depict the tumor nodules.  
 
3.12.3.2 Hematoxylin and eosin (H/E) staining 
Organs were fixed in 4% PFA, embedded in paraffin and cut in 5 µm sections before H/E 
staining was performed. The typical organs with tumor burden, namely liver, spleen, 
stomach and small intestines were investigated to get an idea of the tumor morphology 
(Figure 48). Tumor nodules adhering to the stomach and small intestines were rather solid 
whereas in liver and adherent tissue of the spleen infiltration of tumor cells into healthy 
tissue could also be seen. 
 
Results     75 
21
Control SKOV-3                         SKOV-3
Spleen
Liver
Stomach
Small intestine
10x 2.5x
 
Figure 48. Hematoxylin and eosin staining of SKOV-3LucEGFP i.p. samples and control tissue 
PFA fixed and paraffin embedded tissue samples from mouse 3 at day 45, were cut in 5 µm 
sections and stained with hematoxylin and eosin. Liver, spleen, stomach and small intestine 
samples are illustrated. First column shows a control animal, second (10x magnification) and third 
column (2.5x magnification) shows SKOV-3 LucEGFP implemented tumors. 
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4 DISCUSSION 
4.1 In vitro evaluation of non-covalent Ad coating with PAMAM dendrimers or 
LPEI and BPEI polymers 
Chemical modification of adenovirus capsids with polymers or lipids has been described, 
by several groups, to be beneficial for the reduction of the immune response, enhancement 
of transduction efficiency and targeting to receptors others than CAR.46-48 In this study 
cationic PAMAM dendrimers, linear polyethylenimine (22 kDa) and branched 
polyethylenimine (25 kDa) were utilized to coat the Ad capsid by virtue of electrostatic 
interaction to make cell lines with low CAR levels accessible to Ad infection. Targeting to 
the epidermal growth factor receptor (EGFR) was achieved with the EGFR binding peptide 
GE11, covalently coupled to the PAMAM dendrimers via a 2 kDa PEG spacer. This 
represents a significant alternative to genetic targeting approaches, where ligands are 
usually presented at the distal end of the fiber.109  
Structural studies of Ad/PAMAM G5 complexes by TEM revealed, that mostly single 
capsids and some moderate aggregates existed, which were completely coated with 
PAMAM G5 above a ratio of 200 PAMAM G5 molecules per capsid (Figure 7 and 8). 
Early studies conducted with cationic liposome-coated Ad showed only large aggregates of 
several capsids.72 Nevertheless, for further in vivo studies, e.g., systemic tumor targeting, 
this would be less beneficial. Furthermore the surface charge of Ad/PAMAM G5 
complexes was investigated. When evaluating the surface charge by measuring the zeta 
potential of Ad, coated with increasing amounts of PAMAM G5, a reversal of charge was 
observed after coating, leading to positively charged particles (Figure 9). The reverse in 
surface charge enabled easier binding to the negative cell surface, explaining the 
enhacement in transduction efficiency seen after coating. To check for the stability of the 
complexes in solution and during cellular uptake, co-localisation of Ad-Alexa488 and 
PAMAM G5-Cy5 was analyzed, quantitatively and qualitatively, using the histo and 
profile tool within the Zeiss 510 META software. With a co-localisation coefficient, 
calculated according to Manders,105 of 0.7 to 0.8 a high degree of signal correlation was 
detected within the cells (Figure 14B) and as PAMAM G5 coated Ad was even found in 
the perinuclear region of cells (Figure 13 and 14A), it was deduced that Ad/PAMAM G5 
complexes were transported together once inside the cell, and that coating did not 
adversely affect transport toward the nucleus. After evaluating the level of receptors, 
associated with adenovirus binding and uptake (CAR, αvβ3 integrins) (Figure 18 and S1, 
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supplementary information), in various cancer cell lines, U87MG and HuH7 were chosen 
as cell lines expressing low and high levels of CAR, respectively, to study differences in 
uptake of Ad-Alexa488 versus Ad-Alexa488 coated with PAMAM G5-Cy5. When 
analyzing Ad uptake, semi quantitatively, by flow cytometry, U87MG as a low CAR 
expressing cell line showed highly elevated levels of cellular uptake after coating (Figure 
19A). In contrast, the increase in HuH7 cells was less pronounced, as the uptake rate for 
uncoated Ad in this cell line was already prominent (Figure 19B), probably due to high 
basal levels of CAR. This clearly points to a correlation between high CAR level and Ad 
binding, so that the higher the level the higher the binding, followed by more effective 
cellular uptake. Ad uptake in cells with low susceptibility to transduction could be 
improved through non-covalent PAMAM coating. As the binding capacity of negatively 
charged Ad capsids for cationic molecules is limited, an excess of cationic charge might 
result in free PAMAM molecules, apart from virus bound ones, which can compete for 
cellular uptake. This has already been shown for nonviral transfections, where free 
polycations can be advantageous for the endosomal release of plasmid DNA delivered, but 
at the same time can also compete for cellular uptake.100 In addition, it appears that similar 
effects, in terms of competition, may also occur with Ad. While Ad association could not 
be further boosted using amounts higher than 10 ng PAMAM G5-Cy5, the fluorescent 
signal was increased further at a dose of 100 ng, indicating the uptake of free dendrimer 
(Figure S2, supplementary information). In order to visualize the uptake of PAMAM G5-
Cy5 coated Ad-Alexa488 in U87MG and HuH7 cells, laser scanning microscopy (LSM) 
studies were performed. LSM studies revealed that low amounts of PAMAM G5 enabled 
internalization of small coated Ad particles, whereas with 100 ng there was a tendency 
towards the formation of larger particles, which led to strong aggregation at the membrane 
especially on HuH7 cells (Figure 19H). Additionally, the aggregation behavior of the 
Ad/PAMAM G5 complexes was compared with Ad/LPEI, as it is known that polyplexes 
consisting of LPEI and plasmid can rapidly aggregate on the cell surface, when added to 
the cell culture media.110 When conducting LSM studies, with 10 ng of each polycation, 
LPEI/Ad complexes were found to form large aggregates remaining mostly on the cell 
surface, whereas PAMAM/Ad complexes remained small and were readily internalized 
(Figure 20).  
Initially, cell transductions were carried out in the low and the high CAR expressing cell 
lines U87MG and HuH7 respectively, to determine optimal amounts of PAMAM G5 
needed for Ad coating (Figure 22). In addition, LPEI was utilized for Ad coating, as this 
polycation is currently one of the most efficient transfection reagents on the market for 
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nonviral gene delivery.111 With PAMAM G5, low concentrations boosted transgene 
expression in U87MG cells, but only marginally increased transduction efficiency in HuH7 
cells. In sharp contrast, LPEI only moderately increased the transduction efficiency in 
U87MG cells, whereas in HuH7 cells LPEI led to a strong decrease. These observations 
matched the uptake results which indicated an impaired internalization of Ad/LPEI 
complexes. Interestingly, the beneficial effect was not entirely due to the branched 
(PAMAM) versus linear (LPEI) structure of the polycation, since the beneficial effect of 
coating using the highly branched 25 kDa BPEI, which bears a branch point on about one 
third of nitrogen atoms, was even lower than with LPEI (Figure 23). This is in line with 
higher transfection efficiency for LPEI over BPEI in non-viral gene therapy, where LPEI 
supported microtubule associated transport, whereas BPEI did not.110 One reason for the 
superiority of PAMAM over LPEI and BPEI seemed to be a difference in cellular toxicity: 
It has been shown in earlier studies that the PAMAM G5 dendrimer was virtually nontoxic 
up to a concentration of 20 µg/mL in vitro.74 When comparing PAMAM G5 and LPEI 
polyplexes after systemic administration, in vivo, PAMAM G5 was well tolerated up to a 
dose of almost 7 mg/kg, whereas the LPEI polyplexes 74 and BPEI polyplexes 112 induced 
liver toxicity at 2 mg/kg. In this study a similar trend was observed, where LPEI and BPEI 
coated Ad led to pronounced toxicity, in vitro, above 50 ng/well and 100 ng/well 
respectively, whereas PAMAM G5 was well tolerated up to 1,000 ng/well (Figure 22 C,D 
and 23 C,D). Besides the toxicity observed, the impaired internalization seen for Ad/LPEI 
complexes appeared to be the reason for the lower transduction efficiency. It can be 
concluded from these data, depending on the cell line, that an excess of polycation can 
induce toxic effects (in the case of LPEI), compete with coated Ad for cell uptake or lead 
to accumulation on the cell surface (PAMAM and LPEI on HuH7). It was also apparent, 
that PAMAM coating of Ad could compensate for lack of CAR mediated binding. To 
confirm that uptake by this route also resulted in successful transduction, the increase in 
transduction efficiency obtained with PAMAM G5 coating of Ad was correlated to the 
CAR level in different cell lines with varying CAR expression levels (Figure 25). A clear 
inverse correlation was seen between the CAR expression level and the increase in 
transduction efficiency: in SKOV-3 and U87MG cells, which express low levels of CAR, 
transduction was increased 46- and 38-fold respectively, A549 cells with medium CAR 
expression levels showed a 10-fold increase, whereas in DU145 and HuH7 cells exhibiting 
high CAR expression levels, the increase was marginal. For nonviral polyplexes, it has 
been postulated that cellular binding and internalization occurs via heparan sulfate 
proteoglycans (HSPGs).113 It also seems that polycation coated Ad particles can be 
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retargeted to this pathway, which leads to efficient transduction. Polycation induced 
toxicity usually increases with molecular weight,74 hence lower generation PAMAMs (G2 
and G3) were screened for their ability to improve Ad transduction (Figure 24). Although 
on most cell lines the highest increase was found for PAMAM G5, PAMAM G3 and G2 
also led to considerable enhancement. With the latter PAMAM generations, however, 
higher concentrations were necessary to obtain optimal transduction efficiency. Former 
studies by Haensler et al. demonstrated that only PAMAM G > 4 were able to transfect 
cells with plasmid.114 In the case of Ad/PAMAM complexes the increase in cellular 
binding, followed by enhanced cellular uptake, appeared to be efficient for all dendrimers 
tested, whereas endosomal escape and nuclear translocation of transferred DNA was 
achieved by Ad alone. With a polycationic transfection reagent at hand, which enhances 
both viral and plasmid mediated gene delivery, a side-by-side comparison of both systems 
was conducted (Figure 26). With an optimized plasmid content of 400 ng and PAMAM 
G5/plasmid w/w ratio of 2/1, the luciferase activity measured was still 5-fold below the 
activity achieved with uncoated Ad-EGFPLuc in the low CAR expressing cell line 
U87MG. When calculating the number of DNA molecules used per well, optimal nonviral 
transfection still required a 3,700-fold higher number of gene copies when compared to the 
total Ad particles, and a 57,000-fold higher number in relation to the infectious Ad 
particles. Although the uptake route of both systems (PAMAM polyplex and PAMAM 
coated Ad) was similar, this study confirmed the great potential of Ad, once inside the cell, 
in overcoming intracellular barriers, such as endosomal release and nuclear translocation, 
but especially mediating efficient transcription. According to mathematical models, the 
major advantage of Ad lies in post delivery events, as only a small number of intranuclear 
Ad genomes are necessary to induce high transgene expression levels, i.e., >10,000-fold 
more efficient than plasmid DNA.115 In this study a maximum benefit of 3×105 to 3.7×105, 
taking the whole Ad particles into account and 4.7×106 to 5.8×106, when referring to the 
infectious particles only, was found for HuH7 and U87MG cells respectively, comparing 
DNA/PAMAM G5 with Ad/PAMAM G5 in matters of transgene expression. The 
beneficial effect of PAMAM G5 coating on transduction efficiency was also retained in the 
presence of serum, up to 25%, during the transduction process (Figure 15). Furthermore, in 
the presence of 100% FCS transduction efficiencies of 36% and 58% were retained after 
coating with 10 ng and 100 ng, respectively, illustrating the high integrity of the complexes 
even in the presence of negatively charged albumin.  
After intravascular administration, most Ad subtypes interact with several plasma proteins. 
These interactions determine the fate of the virus: binding of coagulation factor X directs 
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the Ad to the liver leading to hepatocyte transduction,43 complement and scavenger 
receptor binding causes Ad internalization and inactivation by Kupffer cells,39 while the 
high prevalence of adenovirus type 5 neutralizing antibodies in the human population leads 
to inactivation of Ad.116 As repeated application cycles of gene vectors are usually 
necessary for efficient treatment of disease, the high immunogenic potential of 
systemically administered Ad, which will rapidly induce the expression of neutralizing 
antibodies, represents a serious problem. To test how efficiently the PAMAM coat could 
prevent antibody binding, a neutralization assay was performed by preincubating uncoated 
Ad-EGFP and Ad/PAMAM G5 complexes with increasing concentrations of plasma 
pooled from 60,000, mostly seropositive, donors (Privigen®). Thereafter samples were 
incubated with A549 cells. While uncoated Ad was rapidly inactivated, PAMAM G5 
coated Ad infected 65% of the cells, at the same IgG concentration (Figure 27 and S3, 
supplementary information). Antibodies able to neutralize Ad vectors bind epitopes either 
on the hexon or fiber proteins.117 Here, the PAMAM G5 coating seemed to efficiently 
protect Ad capsid proteins from this interaction. To make sure that the effect seen was due 
to masking of the Ad surface by PAMAM and that anti-Ad antibodies were not scavenged 
by free PAMAM dendrimer, an indirect ELISA was performed. Virus particles absorbed 
onto a maxisorb flat bottom plate were incubated with Privigen® dilutions, preincubated for 
30 min at RT with 100 ng of PAMAM G5 or HBG buffer, as control, before addition to 
immobilized Ad. For both, PAMAM G5 and HBG preincubations, similar absorption 
values were observed, indicating that Ad antibodies were able to bind to the Ad surface 
regardless of PAMAM G5 present in the solvent (Figure 28). Additionally PAMAM G2 
and G3 were tested for their protective properties and compared to PAMAM G5 (Figure 
29). PAMAM G5 showed the best protection from neutralizing antibodies followed by G3 
and G2. This was probably due to the higher charge density of PAMAM G5, resulting 
from the doubling of primary amines with every PAMAM generation. As the primary 
amines hold a positive charge at physiological pH, the potential for electrostatic interaction 
with the Ad capsid rises from generation to generation. Besides inactivation by 
neutralizing antibodies, there is a high affinity interaction between the coagulation factor X 
(FX) and the hexon protein, leading to hepatocyte transduction after i.v. administration.43-45 
Therefore, a factor X binding assay was performed to examine the potential of PAMAM 
G5 to abolish FX-hexon interaction and subsequently hepatocyte transduction (Figure 30). 
Ad-EGFP and genetically or chemically FX binding-ablated vectors, as controls, were 
coated with increasing amounts of PAMAM G5 and incubated with SKOV-3 cells with or 
without the addition of physiological concentrations of factor X (8 µg/mL). 72 h after 
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transduction, the cells were analyzed for EGFP expression, revealing that only the control 
vectors showed complete ablation of FX binding. In contrast Ad-EGFP, when coated with 
amounts of PAMAM G5 as small as 10 ng resulted in even higher EGFP levels in the 
presence of FX than uncoated Ad, leading to the hypothesis, that both PAMAM and FX 
contributed to an uptake via heparan sulfate proteoglycans (HSPGs). Only with amounts of 
PAMAM particles in excess of FX molecules, could a reduction in transgene expression, in 
the presence of FX, be seen, without a full abolition of FX-hexon interaction. 
Besides evaluating adenovirus receptors for cell attachment and uptake, the epidermal 
growth factor receptor (EGFR) as a possible targeting receptor was investigated (Figure 18 
and S1, supplementary information). The EGFR is upregulated in several tumors and is a 
valid surface marker for targeting of anticancer drugs. Numerous attempts with adenoviral 
vectors have proven its applicability for targeted gene delivery.118 In principle, Ad 
targeting to the EGFR is possible with a non-mitogenic ligand like cetuximab, an anti-
EGFR chimeric human/mouse antibody, which led to successful internalization into EGFR 
positive cells.85 In this study, the short peptide ligand GE11, which has been identified by 
phage display technique,92 was covalently coupled to the PAMAM dendrimers prior to Ad 
coating. In contrast to the natural ligand EGF, this peptide avoids activation of the EGFR 
after binding, which could otherwise induce mitogenic activity.92,97 In the EGFR 
overexpressing cell line A549, GE11 induced a significant, 2.3-fold higher transgene 
expression level, when compared to the control conjugate PAMAM G2-PEG-Cys lacking 
the ligand (Figure 31). In HepG2, which exhibited only low EGFR levels, no significant 
difference was seen. To prove the specificity of the GE11 mediated targeting effect, A549 
cells were preincubated with mEGF, which led to a profound internalization of the EGFR, 
superior to treatment with Cetuximab, as shown by FACS analysis (Figure 32). Only with 
PAMAM-PEG-GE11 was transgene expression reduced after mEGF preincubtion, whereas 
PAMAM-PEG-Cys was unaffected (Figure 33). This clearly demonstrated the selectivity 
of the system for the EGFR. The affinity of GE11 for the EGFR has been reported to be 
approximately 10−20-fold lower, when compared to EGF.92 Hence, a high number of 
GE11 ligands were necessary to achieve a cooperative binding effect of several GE11 
molecules, in close proximity, in order to cluster EGFR.119 Recently it has been 
demonstrated that GE11 peptide, per se, as a single molecule had no measurable binding 
affinity for the EGFR, but when several peptides, covalently attached to LPEI, were 
incorporated into a particle with nucleic acid, EGFR binding was specific and 
measurable.119 Coating of Ad with PAMAM G2-PEG GE11 led to a significant, but less 
pronounced, targeting effect when compared to other EGFR targeting studies performed 
Discussion                    82 
using the natural ligand EGF covalently coupled either via poly[N-2-
hydroxypropyl)methacrylamide] (HPMA)85 or via biotin-streptavidin interaction.118 
Morrison et al. demonstrated that HPMA-coupled mEGF was still able to activate the 
EGFR leading to its internalization and initiation of downstream signaling.90 From 
previous work, performed in our lab, with non-viral gene carriers we learned that this leads 
to an overall boost in particle uptake due to generally increased surface internalization and 
macropinocytosis induced by EGFR activation.97 Still, GE11 can lead to similar effective 
uptake rates but after prolonged incubation times, with specific binding to the EGFR and 
subsequent actin-mediated internalization.120,121 The absence of EGFR activation by 
PAMAM G2-PEG-GE11, which would otherwise lead to macropinocytosis and mitotic 
activity, in addition to the fact that non-covalent PAMAM coating does not cause ablation 
of viral infection as shown for HPMA coated virus, explains the lower increment in 
transduction efficiency by EGFR targeting. Nevertheless GE11 is a promising and safe 
candidate for adenovirus targeting studies to cancer cells, and has been proven to 
specifically enhance transgene expression in EGFR overexpressing tumors after systemic 
injection of gene carriers.120  
Taken together, PAMAM coating presents a novel strategy for non-covalent coating of 
adenoviral capsids. With covalent linkage of polymers to the Ad capsid a restricted 
endosomal release and interference with intracellular trafficking was often seen;122 this was 
not the case using PAMAM dendrimers in this charged base coating strategy, where 
efficient transduction of cancer cells lacking CAR or with low expression levels was 
achieved. As low CAR and high EGFR level appear to correlate with the aggressiveness 
and state of a tumor,123 this hybrid system, in principle, may be suitable for the treatment 
of metastatic disease. Furthermore, the dose of Ad applied may be reduced due to 
enhanced transduction efficiency by targeting, which reduces toxicity and the immune 
response of the host.  
 
4.2 In vivo evaluation of non-covalent Ad coating with PAMAM G5 dendrimer  
After in vitro evaluation of the non-covalent PAMAM coating of Ad, where PAMAM G5 
proved best in increasing transduction efficiency as well as showing the highest protection 
properties against neutralizing antibodies, in vivo studies were performed. Two different 
PAMAM G5 concentrations, namely 250 ng (equals ~ 200 molecules/Ad) and 1500 ng 
(equals ~ 1000 molecules/Ad) were assessed as a coating for Ad-EGFP. Instead of a 
detargeting from the liver, a targeting of the liver could be found with increased Ad 
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particle numbers revealed by qPCR (Figure 36) as well as increased transgene expression 
seen by fluorometry of liver homogenates and laser scanning microscopy of cryosections 
(Figure 34 and 35). Several biodistribution studies with non-viral vectors showed an 
accumulation of cationic polyplexes mainly in liver, spleen and lungs.124,125 The 
accumulation behavior of non-viral gene delivery systems can be explained by the fact, 
that for therapeutic doses high concentrations of polyplexes are needed, which readily 
aggregate as their concentration increases.126 Also with PAMAM coating of adenoviruses a 
concentration dependent aggregation behavior was observed, in vitro. While coating with 
10 ng of PAMAM G5 led to small particles, easily taken up by the cells (Figure 19), 
coating with 100 ng of PAMAM G5 led to bigger particles and depending on the cell line, 
aggregation at the membrane was more or less pronounced. Similar results were found by 
measurement of particle size, performed in the same concentration rage as the in vivo 
experiments, leading to sizes of the coated Ad-EGFP of 168 nm when coated with 200 
molecules PAMAM/Ad and 1128 nm when coated with 1000 molecules PAMAM/Ad. In 
previous studies it has been shown that even though polyplexes accumulate in the liver, 
transgene expression is relatively low.124,125 Burke et al, who evaluated the stability of 
PEI/DNA complexes showed, that PEI polyplexes remain packaged during circulation in 
serum, therefore preventing degradation of free DNA by nucleases, but are unpackaged 
after entering the liver. The unpacking is believed to be a consequence of competitive 
binding with extracellular matrix components, like collagen and heparan sulfates. A partial 
uncoating of the adenovirus would, in contrast to naked DNA, reveal a gene vector with 
high transduction potential.127 Conform to the factor X binding assay (Figure 30), where 
complete FX binding ablation was not feasible using this non-covalent PAMAM coating 
approach, Ad was possibly still able to infect hepatocytes by bridging the Ad to HSPGs on 
the cell surface, mediated by FX.43 The observed hepatocyte targeting effect of 
Ad/PAMAM versus Ad might also be due to a partial escape from ingestion by Kupffer 
cells, a tendency which was already found, when using 250 ng PAMAM G5 for coating 
(data not shown). In contrast, PAMAM G5 coating of an adenovirus encoding for NIS 
(sodium iodide symporter) performed by Geoffrey Grünwald showed a promising 70% 
detargeting effect from the liver of CD1 nu/nu mice. The sodium iodide symporter can be 
used for imaging guided analysis of biodistribution and the level of transgene expression, 
as it is able to transport radio nuclides such as I123 after effective implementation of the 
NIS protein in the cellular membrane.128 Results were obtained by gamma camera imaging 
as a reduction in I123 uptake in the liver four days after application of Ad-NIS versus Ad-
NIS coated with 300 ng PAMAM G5.129 To rule out differences due to the use of different 
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mouse strains and operator variability, a side by side evaluation of Ad-EGFP ± coating in 
Balb/c and CD1 nu/nu mice was performed, where complex formation as well as i.v. 
application was performed by Geoffrey Grünwald. PAMAM G5 coating of Ad-EGFP led 
to an increase in transgene expression in the livers of both mouse strains, which could be 
confirmed by qPCR showing elevated viral particle numbers after coating, not only in the 
livers, but also in the other organs tested (Figure 37 and S5, supplementary information). 
Differences either in the virus preparation leading to different aggregation behaviors, in 
vivo, or specific characteristics of the transmembrane NIS protein may be a reason for the 
observed differences between Ad-NIS and Ad-EGFP gene transfer. As seen in a study by 
Klutz et al, where LPEI/NIS polyplexes were administered intravenously, functional NIS 
expression in the lungs could be abolished due to LPEI-induced membrane damage.120 
Additionally Ad-NIS showed a higher tendency to form aggregates with a broader size 
distribution after coating with 200 molecules PAMAM G5 per Ad compared to Ad-EGFP 
(Figure 11). As a qPCR for adenoviral fiber led to similar vector genome quantities for 
uncoated and 300 ng PAMAM G5 coated Ad-NIS (Geoffrey Grünwald, unpublished 
observations), complexes might got stuck in the liver sinusoids without efficient 
hepatocellular uptake.  
The in vivo results obtained with Ad-EGFP indicate instability of the Ad/PAMAM G5 
complexes after intravenous application combined with insufficient shielding from 
coagulation factor X. Using PAMAM-PEG-OPSS for covalent attachment of PAMAM to 
an Ad with a genetically introduced cysteine in the hypervariable region 5 (HVR5) of the 
hexon protein, might overcome the problem of insufficient shielding, while grafting the 
PAMAM dendrimer with the peptide ligand GE11 would increase specifity for EGFR 
overexpressing tumors.  
 
4.3. Establishment of a SKOV-3 i.p. mouse model with dual color imaging facility 
Results on biodistribution of intravenously (i.v.) applied Ad-EGFP, coated with PAMAM 
G5 showed an increase in hepatocyte transduction instead of a detargeting from the liver. 
As the complex stability and FX shielding ability of non-covalently coated Ad seemed to 
be insufficient for i.v. administration, an alternative application route, namely 
intraperitoneally (i.p.) application was considered. I.p. application is especially interesting 
for the treatment of ovarian cancer. Ovarian cancer is the most lethal form of gynecological 
malignancy, as the disease is typically detected at a late stage.130 As a consequence, more 
than 70% of patients have intraperitoneal metastasis at the time of diagnosis.131  
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The standard treatment of advanced ovarian cancer is represented by a combination of 
platinum and taxanes directly administered into the peritoneal cavity, following initial 
surgery.132 Beside serious side effects such as neurotoxicity, patients often show a relapse 
within a median time of less than 2 years.133,134 Here adenovirus gene therapy could act as 
an alternative or additive therapy approach. As ovarian cancer dissemination is usually 
confined to the peritoneal cavity even in late stages, Ad can be regionally administered into 
the peritoneal cavity allowing local exposure of lesions to a high vector concentration.135 
Akiyama et al. showed that only 0.03% of Ad could be detected in the bloodstream, 30 min 
after i.p. administration of 1x1010 VP and that no parenchymal liver transgene expression 
was detectable. The primary target of i.p. administered Ad was found to be the 
mesothelium present on the exterior of organs,136 which was infected in a CAR-dependent 
manner. As SKOV-3 cells are known to be low in CAR and therefore hardly transducable 
by Ad alone, 106 other methods are needed to improve transduction efficiency and therefore 
clinical outcome. As proven by in vitro transduction studies, PAMAM dendrimers hold 
great potential to elevate transduction efficiency in CAR negative and low CAR level cell 
lines (Figure 24).  In the case of SKOV-3 LucEGFP, PAMAM coating of Ad led to 
infection of 77-92% of the cells for all three PAMAM generations tested, while Ad alone 
infected only 13% of the cells on average, at a MOI of 125 (Figure 43). On the other hand, 
in high CAR level cell lines restricted internalization of Ad/PAMAM particles was seen, 
leading to reduced transgene expression, when increasing the PAMAM concentration. It is 
therefore interesting to investigate if the transduction of mesothelial cells lining the 
peritoneal organs, which occurs via CAR, would be negatively influenced by the PAMAM 
coating. Besides increasing transduction efficiency, in a CAR independent manner, by 
coating of Ad with PAMAM, the specificity of the system could potentially be increased 
when using target specific receptors. As 60% of ovarian cancers are stated to over-express 
the epidermal growth factor receptor (EGFR),107 proven to be highly expressed in the 
SKOV-3 LucEGFP cells used in this study (Figure 39 and 40), the specificity of the system 
can be increased with the use of PAMAM-PEG-GE11 conjugates. Coating of Ad, using 
PAMAM-PEG-GE11 constructs, showed EGFR specificity in vitro 137 as well as in 
vivo.97,138 For detection purposes, a two colored system was established, with SKOV-3 
LucEGFP expressing enhanced green fluorescent protein (EGFP), and AdmCherry 
encoding for the red fluorescent protein mCherry. The detection of both fluorophores was 
possible, in parallel, using either the same excitation wavelength, but different filters for 
detection, as used for FACS analysis (extinction at 488 nm, detection at 530/40 nm and 
680/30 nm band pass filter for EGFP and mCherry respectively), or by the use of different 
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excitation wavelengths combined with the appropriate filters (excitation at 488 nm, 
detection at 505-530 nm band pass filter for EGFP and excitation at 543 nm, detection at 
560 nm long pass filter for mCherry), as used for LSM studies. The monomeric 
fluorophore mCherry, derived from a protein isolated from Discosoma sp., shows high 
photostability and resistance to photobleaching beside a fast maturation.139 It is suitable for 
combination with the well known and extensively studied EGFP, derived from a protein 
isolated from Aequorea victoria. With the establishment of a dual color system, using Ad-
mCherry and SKOV-3 LucEGFP cells, it can be easily verified that Ad infected, mCherry 
expressing, cells are indeed tumor cells. The use of SKOV-3 LucEGFP cells for the 
establishment of this intraperitoneal ovarian carcinoma mouse model has a further 
advantage as luciferase imaging can be performed to follow tumor growth and find the best 
time point for vector administration.  
The SKOV-3 LucEGFP model is therefore a potentially useful model for studying the 
tumor targeting effect of Ad coated with PAMAM dendrimer conjugates and to 
investigate, how adverse side effects, such as abdominal pain and bowel obstruction 140,141, 
as well as an unsatisfactory tumor transduction, seen in early clinical trials, could be 
overcome.85 
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5 SUMMARY 
Adenovirus type 5 (Ad) based vectors are the most commonly investigated gene transfer 
vectors in clinical trials to date due to their high gene transduction efficiency. Transduction 
efficiency of Ad is dependent on the presence of cellular receptors used to mediate Ad 
binding and uptake. The coxsackie- and adenovirus receptor (CAR), which is stated to be 
the key player for efficient cell infection, is often downregulated in tumor cells, correlating 
with disease progression. Therefore methods have to be established to increase 
transduction in these Ad-refractory cancer types.  
In this thesis cationic PAMAM dendrimers generation 2, 3, and 5 were used for non-
covalent coating of the negatively charged adenovirus capsid by the virtue of electrostatic 
interaction. Complexes were studied with respect to their biophysical and biological 
properties. Co-localisation studies using Ad-Alexa488 as well as PAMAM G5-Cy5 
confirmed the high stability of the complexes also during cellular binding and uptake. 
Intracellular trafficking which is often restricted when using covalent coating strategies, 
was thereby not impaired. Additionally, PAMAM dendrimers showed great potential in 
increasing transduction efficiency of CAR negative to medium CAR level cancer cell lines, 
while showing no toxicity up to a concentration of 1 mg/well. Therefore PAMAM 
dendrimers proved superior to commonly used Ad coating polymers based on 
polyethylenimine in relation to enhanced transduction as well as reduced toxicity. As the 
majority of the human population carries anti-Ad antibodies it was important, in regards to 
future clinical applications, to check the protective abilities of the different PAMAM 
generations. Protection from neutralizing antibodies prevents loss of functional vector after 
application and, if needed, might allow second and third rounds of vector administration. 
PAMAM G5, with 128 primary amines and therefore the highest potential for electrostatic 
interaction with the negatively charged Ad capsid, gave the highest protection from 
neutralizing antibodies, followed by G3 and G2.  
To increase the specificity for cancer cells, PAMAM conjugates were synthesized, 
carrying the epidermal growth factor receptor-targeting ligand GE11 covalently coupled to 
the PAMAM dendrimers via a 2 kDa PEG spacer. The PEG spacer had the function of 
presenting the GE11 on the particle surface to make it available for receptor interaction. In 
contrast to the natural ligand EGF, GE11 shows a much lower mitotic activity, making it 
favorable for clinical applications. Coating of the Ad with PAMAM-PEG-GE11 
conjugates led to specific uptake in EGFR overexpressing A549 cells. This could be 
proven by EGFR downregulation prior to transduction, along with the help of a control 
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construct, carrying a terminal cysteine instead of the GE11 peptide. Furthermore HepG2 
cells were used as control cell line expressing low EGFR levels.  
When considering therapy of tumor metastases, intravenous injection of the adenovirus 
vector would be favorable. Liver toxicity however is profound after i.v. application as the 
Ad has a natural tropism for the liver due to clearance by KCs as well as transduction of 
hepatocytes mediated by coagulation factor X-hexon interaction. Ablating this inherited 
tropism was the goal of several studies on genetic and chemical modifications of the virus 
capsid. A vector designed to prevent liver targeting and with increased circulation kinetics 
would have the possibility of accumulating in tumors by the enhanced permeability and 
retention (EPR) effect. Based on the in vitro data gained in this study, Geoffrey Grünwald 
was able to show a detargeting from the liver of 70%, when using 300 ng PAMAM G5 for 
coating of an intravenously administered Ad encoding for the sodium iodide symporter 
(NIS). This could not be repeated in this study using an Ad encoding for enhanced green 
fluorescent protein (EGFP). The influence of the virus preparation, as well as the specific 
characteristics of the NIS transgene, has to be further elucidated to understand the 
requirement for non-covalent coating approaches to mediate efficient liver detargeting.  
Intraperitoneally (i.p.) Ad application is, beside intravenous administration, an interesting 
application route, when thinking about the treatment of ovarian tumors. In order to study 
transduction enhancement of PAMAM dendrimers in vivo, a SKOV-3 ovarian carcinoma 
mouse model was established. Ovarian carcinomas are known to be restricted mostly to the 
peritoneal cavity even in a late stage of disease. Using i.p. implanted SKOV-3 tumors 
offers the possibility of applying Ad locally, circumventing the sequestration of Ad in the 
liver, seen after intravenous administration. SKOV-3 cells are known to be hardly 
transducable by Ad alone due to a low and inhomogeneous CAR expression and show a 
high EGFR level. In this thesis enhancement of transduction as well as specificity for the 
EGFR could be shown, in vitro, using a two color system. The feasibility of a side by side 
evaluation of EGFP expressing SKOV-3 LucEGFP cells and mCherry expressing Ad 
transduced cells, makes an estimation of target versus non-target Ad-infected cells 
convenient. 
Non-covalent coating of the Ad using PAMAM dendrimers holds great potential for 
increasing transduction efficiency in otherwise refractory cancer cells in vitro. Further 
studies are required to see if i.p. administered Ad can overcome difficulties associated with 
Ad therapy in clinical trials of ovarian carcinoma, to date, such as bowel obstruction and 
low transduction efficiency.  
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7 APPENDIX 
7.1 Abbreviations  
Ad   Adenovirus type 5 
BPEI   Branched polyethylenimine (25 kDa)  
CAR   Coxsackie- and adenovirus receptor 
C4BP   C4b-binding protein 
CD4   Cluster of differentiation 4 
CpG   Cytosine phosphate guanine 
Cy5   Cyanine 5  
Cys   Cysteine  
CR-3   Complement receptor 3 
CsCl   Cesium chloride 
D   Aspartic acid 
DAB   Diaminobutane  
DAPI   4',6-Diamidino-2-phenylindole  
DLS   Dynamic light scattering  
DMEM  Dulbecco’s Modified Eagle’s Medium  
DMSO  Dimethyl sulfoxide  
DNA   Deoxyribonucleic acid  
DTT   Dithiothreitol  
EDTA   Ethylenediaminetetraacetic acid 
EGFP   Enhanced green fluorescent protein 
EGF   Epidermal growth factor 
EGFR   Epidermal growth factor receptor  
EPR effect  Enhanced permeability and retention effect    
EtBr   Ethidium bromide  
EtOH   Ethanol 
FACS   Fluorescence-activated cell sorting  
FCS   Fetal calf serum 
FGF   Fibroblast growth factor 
FGFR   Fibroblast growth factor receptor 
FS   Forward scatter 
FIX   Coagulation factor IX 
FX   Coagulation factor X 
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G   Glycine 
GM-CSF  Granulocyte macrophage colony stimulating factor 
HBG   HEPES-buffered glucose  
HBS   HEPES-buffered saline 
HEK 293  Human embryonic kidney cells 
HEPES  N-(2-hydroxyethyl) piperazine-N’-(2-ethansulfonic acid)  
H-L-Cysteine  L-Cysteine hydrochloride monohydrate 
HPLC   High pressure liquid chromatography 
HPMA  N(2-hydroxypropyl)methacrylamide 
Hsc70   Heat shock cognate 70 kDa protein  
HSV-TK  Herpes simplex virus thymidine kinase 
HVR   Hypervariable region 
IgG   Immunoglobulin G 
INF   Interferon 
i.p.   Intraperitoneal 
i.v.   Intravenous 
K   Lysine 
kb   Kilobase 
kDa   Kilo Dalton 
KCs   Kupffer cells 
LPEI   Linear polyethylenimine (22 kDa)  
LSM   Laser scanning microscopy 
Luc   Luciferase  
mEGF   murine epidermal growth factor 
MFI   Mean fluorescence intensity 
miRNA  Micro RNA  
MOI   Multiplicity of infection 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MW   molecular weight  
NEAA   Non essential amino acids 
NIS   Sodium iodide symporter 
NPC   Nuclear pore complex 
OPSS   =PDP, Ortho-pyridyldisulfide 
o.n.   over night 
p53   Protein 53 
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PAMAM  Polyamidoamine dendrimer 
PBS   Phosphate-buffered saline  
PCR   Polymerase chain reaction 
pDNA   Plasmid DNA  
PDI   Polydispersity index 
PDP   Pyridyldithio propionyl group 
PEI   Polyethylenimine  
PEG   Polyethylene glycol  
PFA   Paraformaldehyde 
PFU   Plaque forming units 
PG 2/3/5  PAMAM generation 2/3/5 
PMSF   Phenylmethylsulfonyl fluoride 
PTA   Phosphotungstic acid 
qPCR   Quantitative real time PCR 
R   Arginine 
RLU   Relative light units 
RNA   Ribonucleic acid  
ROI   Region of interest 
RPMI   Roswell Park Memorial Institute 
RT   Room temperature 
SS   Sideward scatter 
SR-A   Scavanging receptor-A 
TEM   Transmission electron microscopy  
T   Threonine 
Tf   Transferrin 
TfR   Transferrin receptor 
TFA   Trifluoroacetic acid 
TFP   Tetrafluorophenyl esters 
TGF beta  Transforming growth factor beta 
TNBS   Trinitrobenzenesulfonic acid  
TP   Terminal protein 
TRAIL  Tumor Necrosis Factor Related Apoptosis Inducing Ligand 
Tris   Tris(hydroxymethyl)aminomethane 
VP   Viral particles 
w/w ratio  Weight to weight ratio (conjugate to nucleic acid)
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7.2 Buffer List 
 
Buffer/ Solution Ingredient Amount 
DMEM  
(low glucose, 
1g/L) 
 
Biochrom DMEM medium powder 
NaHCO3 
FCS 
Penicillin 
Streptomycin 
Stable glutamine 
(NEAA if required) 
Adjusted to pH 7.4 
10.15 g/L 
3.7 g/L 
10% 
1% 
1% 
1% 
1% 
DMEM/Ham’s 
F12 
1:1 
Biochrom DMEM/Ham F12 medium powder 
NaHCO3 
FCS 
Penicillin 
Streptomycin 
Stable glutamine 
Adjusted to pH 7.4 
12.12 g/L 
2.44 g/L 
10% 
1% 
1% 
1% 
RPMI Biochrom RPMI 1640 medium powder 
NaHCO3 
FCS 
Penicillin 
Streptomycin 
Stable glutamine 
Adjusted to pH 7.4 
10.48 g/L 
2 g/L 
10% 
1% 
1% 
1% 
PBS 
 
KCl 
KH2PO4 
NaCl 
Anhydrous Na2PO4 
Adjusted to pH 7.4 
MilliQ water 
0.2 g 
0.2 g 
8.0 g 
1.15 g 
 
ad 1000 mL 
HBG 
 
HEPES (20 mM) 
Glucose monohydrate 
pH adjusted to 7.4 
MilliQ water 
4.76 g/L 
55 g/L 
 
ad 1000 mL 
LAR 
 
1 M glycylglycine solution (pH 8.0) 
100 mM MgCl2 solution 
0.5 M EDTA solution (pH 8.0) 
DTT  
ATP 
Coenzyme A (stock: 42.6 mg/mL) 
pH adjusted to 8.0-8.5 
MilliQ water 
Luciferine-Solution (stock: 10 mM) 
2 mL (20 mM) 
1 mL (1 mM) 
20 µL (0.1 mM) 
50.8 mg (3.2 mM) 
27.8 mg (0.55 mM) 
0.5 mL (0.27 mM) 
 
ad 100 mL 
ad 0.5 mM 
Luciferine stock 
(10 mM) 
Luciferine-Na 
1 M glycylglycine solution (pH 8.0) 
pH adjusted to 8.0 
MilliQ water 
240 mg 
2.35 mL 
 
ad 80 mL 
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7.2 Buffer list continued 
Buffer/ Solution Ingredient Amount 
LB  Bacto trypton 
Yeast extract 
NaCl 
MilliQ water 
For agar plates: 
Agar 
Relevant antibiotics in working conc.: 
Ampicillin (100 µg/mL) 
Kanamycin (50 µg/mL) 
Zeocin (25 µg/mL) 
10 g 
5 g 
5 g 
ad 1 L 
 
15 g/L 
50xTAE Tris 
EDTA-Na2x2H2O 
Eisessig 
242.3 mg 
18.6 g/L 
60.05 g/L 
NaOAc (3M) NaOAc 
pH adjusted to 5.2 with HOAc 
MilliQ water 
12.3g 
 
ad 50 mL 
Tris/EDTA 
(10mmol/1mmol) 
Tris 
EDTA (stock: 0.5M, pH 8 with NaOH) 
pH adjusted to 8.5 
MilliQ water 
 
121.14 mg 
200 µL 
 
ad 100 mL 
ELISA 
Coating Buffer 
 
0.2 M NaHCO3  
0.2 M Na2CO3  
pH 9.5
 
 
100 mL 
 50 mL 
Blocking Buffer BSA 
PBS 
7.5 g 
ad 250 mL 
Wash Buffer 
0.05 % Tween 
Tween 20 
PBS 
0.5 g 
ad 1000 g 
Substrate 
solution 
0.2 M Na2HPO4  
1M Citric acid  
pH adjusted to 5 
MilliQ water 
o-Phenylendiamine dihydrochoride (Sigma) 
30% H2O2 
2.57 mL 
2.43 mL 
 
ad 10 mL 
2 tablets 
4 µL 
RIPA Buffer Tris 
NP-40  
Na-deoxycholate  
NaCl  
EDTA (stock 0.5M) 
pH adjusted to 7.4 
MilliQ water 
PMSF (protease inhibitor, stock 200mM) 
6.072 g 
10 mL 
2.5 g 
8.75 
2 mL 
 
ad 1000 mL 
5mL 
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7.3 Supporting information chapter 3.4 
Receptor level study 
SKOV-3: 0.38%
MFI: 2.6
U87MG: 3.51%
MFI: 2.98
A549: 99.21%
MFI: 35.6
DU145: 99.93%
MFI: 122.29
HuH7: 99.99%
MFI: 142.99
HepG2: 100%
MFI: 222.84
CAR
CAL-33: 99.91%
MFI: 34.56
FaDu: 72.88%
MFI: 7.89
HEK293: 99.91%
MFI: 101.88
K562: 6.11%
MFI: 7.06
U87MGwtEGFR: 59.91%
MFI: 6.38
U373: 97.40%
MFI: 20.34
 
SKOV-3: 0.60%
MFI: 2.66
U87MG: 99.07%
MFI: 13.18
HuH7: 2.57%
MFI: 3.57
HepG2: 0.16%
MFI: 2.65
DU145: 91.90%
MFI: 22.34
A549: 29.36%
MFI: 10.72
Integrin
CAL-33:  0.05%
MFI: 2.71
FaDu: 0.31%
MFI: 2.48
HEK293: 14.68%
MFI: 4.47
K562: 1.43%
MFI: 3.24
U373: 82.29%
MFI: 14.06
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Receptor level study continued 
A549: 99.99%
MFI: 213.93
DU145: 99.99%
MFI: 149.46
HepG2: 29.34%
MFI: 6.64
HuH7: 100%
MFI: 197.69
SKOV-3: 1.09%
MFI: 2.94
U87MG: 99.95%
MFI: 26.21
EGFR
CAL-33: 99.98%
MFI: 347.42
FaDu: 100%
MFI: 384.61
HEK293: 99.20%
MFI: 17.27
K562: 0.37%
MFI: 2.95
U87MGwtEGFR: 100%
MFI: 289.79
U373: 99.87%
MFI: 71.80
 
A549: 99.68%
MFI: 44.71
DU145: 99.74%
MFI: 111.50
Hep G2: 99.63%
MFI: 38.72
HuH7: 99.61%
MFI: 66.37
SKOV-3: 0.14%
MFI: 2.53
U87MG: 97.58%
MFI: 42.83
TfR
CAL-33: 99.96%
MFI: 134.23
FaDu: 99.98%
MFI: 179.27
HEK293: 99.61%
MFI: 23.22
K562: 99.15%
MFI: 309.07
U87MGwtEGFR: 99.86%
MFI: 41.45
U373: 99.92%
MFI: 70.87
 
Figure S1. Receptor level estimation of CAR, integrin αvβ3, EGFR and TfR  
Indicated cell lines were stained for CAR, integrin αvβ3, EGFR and TfR and analyzed by flow 
cytometry. Control staining was performed with mouse IgG control antibody. 
For every cell line, the mean fluorescence intensity (MFI) in the FITC channel, as well as the 
percentage of receptor positive cells is shown, going from the receptor low cell lines in the upper 
left corner to the receptor high cell lines in the lower right corner, for every receptor tested. 
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7.4 Supporting information chapter 3.5 
Co-localisation study by FACS analysis 
 
 
Figure S2. Cellular association of Alexa488-labeled Ad and Cy5-labeled PAMAM G5 dendrimer 
5x104 U87MG and HuH7 cells seeded in 24-well plates were transduced with Ad-Alexa488 alone 
or coated with indicated amounts of PAMAM G5-Cy5 (MOI 500, 10,000 virus particles/cell). After 
a 2 h incubation period, at 37 °C, cells were analyzed by flow cytometry. Dot plots of 10,000 gated 
events (x-axis: Ad-Alexa488 signal, y-axis: PAMAM G5-Cy5 signal) of U87MG (top row) or 
HuH7 cells (bottom row) are shown. 
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7.5 Supporting information chapter 3.7 
Neutralization assay on cellular level 
Ad + IgG
98.30%                  79.19%                    38.52%                    4.78%                     0.80%                 0.45%
 
Ad/25ng PAMAM G5 + IgG
99.10%                  87.82%                77.45%                  65.04%                  43.92%                  23.02%
Ad/100ng PAMAM G5 + IgG
97.29%                   83.74%               81.43%                   76.89%                  65.27%                  47.94%
 
Figure S3. The protective effect of PAMAM G5 coating on transduction in the presence of anti-
adenovirus neutralizing antibodies 
5x104 A549 cells, seeded in 24-well plates, were transduced with Ad-EGFP alone (triangles) or 
coated with 25 ng or 100 ng of PAMAM G5 at a MOI of 100. A range of IgG concentrations 
(Privigen®) were incubated with uncoated Ad or Ad/PAMAM G5 complexes for 30 min before 
application to A549 cells. After 48 h, EGFP expression was analyzed by flow cytometry. The first 
row in each panel shows histograms, illustrating the shift of EGFP positive cells. The second row 
in each panel shows density plots depicting the amount of EGFP positive cells. Representative data 
out of three independent experiments are shown.  
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7.6 Supporting information chapter 3.10 
Biodistribution study with Ad/PAMAM G5 250ng 
A
 
B
Control Ad-GFP                      Ad/PG5-PEG-Cys      Ad/PG5
Liver
Spleen
 
Spleen LiverC D
 
Figure S4. Biodistribution study after application of Ad-EGFP or Ad/PAMAM G5 250 ng  
(A) Fluorometric measurement of liver homogenates of Balb/c after intravenous injection of 
3x1010VP of Ad-EGFP (light grey triangles), Ad/PAMAM G5-PEG-Cys 250 ng (dark grey 
squares) or Ad/PAMAM G5 250 ng (black squares). (B) Cryosections of spleen (top row) and liver 
samples (bottom row) showing a representative of each treatment group plus an untreated control 
animal. (C, D) QPCR of spleen (C) and liver (D) samples of Ad-EGFP (light grey triangles), 
Ad/PAMAM G5-PEG-Cys 250 ng (dark grey squares) or Ad/PAMAM G5 250 ng (black squares). 
n=3 per group, plus untreated control animal.  
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7.7 Supporting information chapter 3.11 
Cryosections – Biodistribution study with two mouse strains 
Balb C, Kidney
Control Ad GFP M1 M2
M3 M4 M5
Control Ad/PG5 300ng  M1             M2
M3 M4 M5
Control
Ad-GFP                                                                              Ad-GFP/ PG5 300 ng
 
Control Ad GFP M1 M2
M3 M4         M5
Control Ad/PG5 300ng M1 M2
M3 M4         M5
Balb C, Lung
44
Ad-GFP                                                                               Ad-GFP/ PG5 300 ng
Balb C, Spleen
Control Ad GFP M1 M2
M3 M4         M5
Control Ad/PG5 300ng M1 M2
M3 M4         M5
Ad-GFP                                                                             Ad-GFP/ PG5 300 ng
 
Control Ad GFP M1 M2
M3 M4         M5
Control Ad/PG5 300ng M1 M2
M3 M4         M5
Balb C, Liver
45
Ad-GFP                                                                             Ad-GFP/ PG5 300 ng
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Cryosections – Biodistribution study with two mouse strains continued 
Control Ad/ GFP M1 M2
M3 M4         M5
196
Control Ad/PG5 300ng M1 M2
M3 M4         M5
CD1 nu/nu, Kidney Ad-GFP                                                                          Ad-GFP/ PG5 300 ng
 
CD1 nu/nu, Lung
Control Ad/ GFP M1 M2
M3 M4         M5
Control Ad/PG5 300ng M1 M2
M3 M4         M5
Ad-GFP                                                                             Ad-GFP/ PG5 300 ng
 
Control Ad/ GFP M1 M2
M3 M4         M5
Control Ad/PG5 300ng M1 M2
M3 M4         M5
CD1 nu/nu, Spleen Ad-GFP                                                                           Ad-GFP/ PG5 300 ng
 
CD1 nu/nu, Liver
Control Ad/ GFP M1 M2
M3 M4         M5
Control Ad/PG5 300ng M1 M2
M3 M4         M5
47
Ad-GFP                                                                              Ad-GFP/ PG5 300 ng
 
Figure S5. Cryosections after i.v. application of Ad versus Ad/PG5 in Balb/c versus CD1 nu/nu 
LSM images of cryosections of kidney, lung, spleen und liver of two different mouse strains, 
Balb/c and CD1 nu/nu, after application of 2.2x1010 VP Ad-EGFP or Ad-EGFP coated with 300 ng 
PAMAM G5 (PG5). 
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7.8 Supporting information chapter 3.12 
Diagonal gating to find the best channel combination for mCherry evaluation 
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Figure S6. Optimization of diagonal gating with different channel combinations 
To find the best channel combination for diagonal gating, cells excitated with a 488 nm or 635 nm 
laser respectively were plotted against the FITC channel (530/40) using either the PE (575/25),  
PE-Texas Red (613/20), PE-Cy5 (680/30), PE-Cy7 (750 LP) or APC (665/20) channel for diagonal 
gating. Excitation with the 488 nm laser and diagonal gating of PE-Cy5 against the FITC channel 
resulted in the best separation between mCherry positive and negative cells. Almost equivalent 
results were found with PE-Texas Red against the FITC channel. 
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Transduction of SKOV-3 LucEGFP with Ad-mCherry - overview 10x 
A B
C D E
(A) Control
(B) Ad 125
(C) Ad/PG2 500ng
(D) Ad/PG3 100ng
(E) Ad/PG5 25ng
 
Figure S7. Evaluation of the coating benefit of PAMAM G2, G3 and G5 by LSM using Ad-
mCherry at a MOI of 125 
2.5x104 SKOV-3 LucEGFP cells seeded in 8-well chamber slides were transduced at a MOI of 125 
with Ad-mCherry alone or coated with the indicated amounts of PAMAM G2, G3 and G5. After an 
incubation time of 48 h, cells were subjected to LSM imaging. (A-E) Laser scanning microscopy 
(LSM) images of control cells (A) versus Ad-mCherry only (B) and Ad-mCherry coated with 
PAMAM G2 (C), G3 (D) and G5 (E). Pictures show the EGFP signal from SKOV-3 LucEGFP as 
well as the mCherry signal in a 10x magnification.  
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